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Many biomaterials are being researched for applications in tissue regeneration, but so 
far, none have led to successful disease modification of osteoarthritis (OA). This 
dissertation details the application of several biomaterials, including ECM and a peptide-
polymer, for OA treatment. The first segment details the use of porcine urinary bladder 
matrix in a post-traumatic mouse model of OA. The second segment details the use and 
optimization of a hyaluronic acid binding peptide in a post-traumatic mouse model of 
OA. These studies focus on the potential OA disease modifying activity of applying these 
therapies intra-articularly to the joint. This work resulted in improved OA disease 
outcome in a post traumatic mouse model of OA. However, this work led us to question 
the nature of the immune system in the OA microenvironment to help better understand 
the state of the knee joint, which will help inform future therapies. The final segment of 
the dissertation details the study of immune cells in the OA microenvironment during the 
course of post-traumatic OA progression. This work elucidated alterations in cytokines 
and immune cell populations that have not previously been studied in OA. These cells 
and cytokines are new potential targets for OA therapy.  
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This introduction has been reprinted with permission from Elsevier  
This chapter was published in Principles of Regenerative Medicine 3rd Edition, by Anthony 
Atala, Robert Lanza, Tony Mikos. Cartilage Tissue Engineering, Copyright Elsevier (2018) 
 
Abstract 
Tissue engineering aims to repair injured and diseased tissue to restore function. 
Cartilage is an integral component of the joint and the degeneration of the articular 
cartilage leads to osteoarthritis. Traditional approaches for engineering cartilage to treat 
osteoarthritis (OA) employ cells, scaffolds, and biological signals or growth factors, 
alone or in combination.  Cartilage has been engineered both in vitro and directly in vivo. 
This research has resulted in numerous therapies in development and clinical testing, as 
well as some clinically approved products for treating cartilage defects in OA patients. 
However, clinical efficacy in a broad patient population remains a challenge. Defining 
the impact of a diseased or inflammatory environment, such as occurs with OA, on 
cartilage tissue engineering is an area of growing interest that will lead to approaches to 
further increase the efficacy these new therapies. This chapter will also discuss future 
perspectives in the field, highlighting new research on the role of immune environment in 
tissue regeneration and the potential impact on cartilage.  
 
Key Words: Cartilage, engineering, scaffold, immune system, osteoarthritis 
Cartilage and Cartilage Repair 
Cartilage is a connective tissue that functions to provide form, strength, and support. 
There are three types of cartilage distinguished by their molecular components in the 
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extracellular matrix (ECM), their anatomical location, and their function. Hyaline 
(articular) cartilage has a white glassy appearance and is found primarily in articulating 
joints. Its ECM is mainly composed of water, hyaluronate, proteoglycans, and type II 
collagen. Hyaline cartilage functions to provide stable movement with minimal friction. 
It has high viscoelasticity and demonstrates an excellent ability to provide resistance to 
compression and cushion the impact caused by physical load during movement (1). 
Elastic cartilage is distinguished by the presence of elastin in the ECM. Elastic cartilage 
provides a structural function, represented by the support it provides in the external ear. 
Lastly, fibrocartilage has a higher proportion of type I collagen in its ECM. Fibrocartilage 
is found in the meniscus, intervertebral disc and at the distal region of tendons and 
ligaments in apposition to bone, providing tensile strength and countering compression 
and shear forces (2). 
All of the three types of cartilage feature a sparse cellularity, limited blood supply, and lack of 
neural innervations. These cartilages have intrinsically poor reparative capabilities due to their 
purported inability to form a clot to attract the necessary fibroblasts and start subsequent tissue 
synthesis for repair (3).  Once defects, even very small ones, are initiated in cartilage, the 
degradation process is progressive (4). One of the irreversible consequences of the destruction of 
articular cartilage is arthritis, a leading cause of disability. Osteoarthritis (OA), the most common 
type of arthritis, is characterized by articular cartilage loss and degeneration, subchondral bone 
thickening, osteophyte formation, and joint inflammation (5). OA is widespread globally in 60–
70% of people older than 65 years of age (6-8). Over 21 million people are suffering from this 
disease in the USA, and 10% of cases are estimated to be caused by previous trauma to the 
weight-bearing joints, which is classified as post-traumatic osteoarthritis (PTOA) (9). PTOA 
develops not only in elderly people, but also in young people suffering the results of previous 
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trauma. Once a cartilage defect is present, cartilage matrix continues to be lost while the 
surrounding tissues become more inflamed and contribute to further cartilage matrix destruction 
(10). This causes significant pain, disability, and morbidities, strongly affecting an individual’s 
capacity to live a full and active life. 
Current surgical treatment options available for focal cartilage repair include 
microfracture and osteochondral autografting. Microfracture may be considered a current 
standard for cartilage repair and is a low cost and minimally invasive procedure (11, 12). 
This technique employs subchondral drilling to initiate cartilage repair by inducing 
bleeding, enabling mesenchymal progenitor cells from the bone marrow to migrate into 
the lesion site. After this procedure, the repair tissue appears to be a cartilage-like 
substitute but is primarily composed of fibrocartilage. Unfortunately, the repair 
fibrocartilage has inferior quality and longevity compared to the native hyaline cartilage, 
thus only delaying cartilage degeneration for a few years (12). Osteochondral 
autografting or mosaiplasty is a technique of autotransplantation in which osteochondral 
plugs are harvested from non-weight-bearing or low-weight-bearing regions of the joint 
and implanted into defects that have been prepared and sized. In clinical testing, survival 
of the transplanted hyaline cartilage has been reported in 85% of patients, with a 91% 
good to excellent clinical outcome reported by patients followed for 3–6 years (13, 14). 
Additionally, follow up 10 years after surgery demonstrated improved clinical outcomes 
compared to microfracture (15). However, the cartilage autografts suffer from many 
problems including limited donor tissue availability, donor site injury, scarring, and pain, 
prompting the development of an innovative bioengineered therapy called autologous 
chondrocyte implantation (ACI), which will be discussed later in this chapter (16, 17). 
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Allograft tissue transplants address the donor tissue availability challenge and are a fast 
growing therapy.  
Tissue Engineering for Cartilage Regeneration 
To overcome the treatment obstacles of the available surgical options for cartilage 
repair, the reconstruction of cartilage using tissue engineering techniques has attracted 
tremendous attention. Tissue engineering is a multidisciplinary field that applies the 
principles of engineering, life sciences, cell and molecular biology to the development of 
biological substitutes that restore, maintain, and improve tissue function (18). The 
historical approach to cartilage engineering is to select and optimize the following 
components to be used individually or in combination to regenerate organs or tissues:  (1) 
reparative cells that can form a functional matrix, (2) an appropriate scaffold for 
transplantation and support, and (3) bioreactive molecules, such as cytokines and growth 
factors, that will support and choreograph formation of the desired tissue (19).  Biological 
cues and key biological factors that promote tissue repair in the local in vivo tissue 
environment continue to be discovered and developed, propelling the field forward. For 
example, the innate and adaptive immune systems are newly appreciated factors for 
successful tissue engineering. The immune system participates in many facets of tissue 
repair via scavenging dead cells and debris, inducing vascularization of injured tissue, 
and recruiting progenitor cells to tissue (20-22).  More specifically, Badylak discovered 
that macrophage phenotype is important in muscle remodeling, and that macrophage 
phenotype is influenced by ECM scaffolds implanted into a muscle wound (23). Sadtler 
found that CD4+ Th2 cells were necessary for pro-regenerative macrophage polarization 
and subsequent muscle regeneration after a treatment with ECM scaffolds, concluding 
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that the adaptive immune system as well as the innate immune system are important for 
functional tissue regeneration with a scaffold (24). Although little is known about how 
either innate or adaptive immune cells may be involved in cartilage regeneration, it is 
likely to be a future focus for the field (Figure 1).   
Cartilage surface modification 
Engineering therapies aimed to prevent cartilage deterioration after injury are valuable 
considering that cartilage is extremely difficult to repair. As lubrication of the cartilage surface is 
extremely important for its proper movement without friction and mechanical degradation, 
viscosupplementation is a common procedure. Viscosupplementation replenishes the molecules 
in the synovial fluid that naturally lubricate the cartilage surface, most commonly hyaluronic 
acid. One strategy is to enhance viscosupplementation with synthetic molecules such as a 
hyaluronic acid binding peptide to further enhance the retention of hyaluronic acid at the joint 
surface (25, 26). Synovial fluid can also be enhanced with synthetic charged polymers and 
synthetics with large molecular brush structures (27). Synthetic lubricin, synthetic mimics of 
lubricin, and recombinant lubricin have also been created to replenish lubricin lost at the 
beginning of cartilage degeneration before major structural cartilage changes have occurred (28). 
These lubricin mimics bind hyaluronic acid to the cartilage surface, increasing boundary layer 




Cell types for cartilage repair 
Different cell sources are available to provide reparative tissue including 
differentiated cells, mesenchymal stem cells (MSCs), and embryonic progenitor 
cells. Chondrocytes and MSCs are the two most investigated cell sources for 
cartilage tissue engineering. Here, I will focus on MSCs. MSCs are attractive cells 
for repairing cartilage because in addition to their ability to differentiate into 
chondrocytes, MSCs have immunomodulatory properties. MSCs can migrate to 
sites of inflammation, and can modulate lymphocyte cell function  through several 
growth factors and cytokines including TGF-β1, nitric oxide, and IL-10 (29). This 
immunomodulation is especially important when considering the destructive 
environment in which a cartilage construct is likely to be implanted. MSC 
therapies for OA are currently undergoing clinical trials, but not many long-term 
results are currently available. Therapies being tested include injection of MSCs 
isolated from different sources, MSC injection with additional biological factors, 
and injection of ex vivo expanded MSCs (30). A clinical trial of bone marrow 
derived MSC injections showed improved WOMAC scoring over one-year post 
treatment, indicating decreased pain and increased function. Additionally, X-ray 
and MRI findings indicated that MSC treatment may halt the progression of 
cartilage loss (31). However, a common problem with MSC therapy is the poor 
delivery and retention of MSCs at the cartilage defect site. There are preclinical 
models aimed at optimizing MSC delivery, however most clinical trials inject MSCs 
free of scaffold (30).Bioscaffolds in cartilage repair 
Tissue engineering scaffolds are designed to provide a 3D environment to support and 
direct cellular processes in their migration, proliferation, and differentiation toward 
functional tissue. Scaffolds can be applied with cells, however applying scaffold without 
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cells is becoming more attractive because cell therapy is costlier. The selection of 
bioscaffolds for cartilage engineering requires complex mechanical properties that can 
support cellular functions, biocompatibility, capability of waste and nutrient transport, 
and sufficient structural integrity for joint reconstruction. Both natural and synthetic 
materials have been applied as cartilage tissue engineering scaffolds in a variety of forms, 




Collagen is the primary structural protein found in both bone and cartilage (32, 33). As 
such, collagen-based scaffolds are theoretically capable of supporting chondrocyte 
attachment and function. They are also biocompatible and biodegradable. Collagen 
scaffolds have been used in a wide variety of forms such as gels, membranes, and 
sponges into which cells and/or bioactive factors may be introduced (34, 35). Pieper et al. 
utilized a cross-linked porous type II collagen sponge to support the proliferation and 
differentiation of chondrocytes under cell culture condition up to 14 days (34). 
Yokoyama et al. cultured MSCs in a collagen gel matrix in a chondrogeneic medium 
supplemented with bone morphogenetic protein-2 (BMP-2), transforming growth factor-
β3 (TGF-β3), and dexamethasone (36). The constructs were characterized by a 
downregulation of type I collagen, and upregulation of type II collagen and the cartilage-
related proteoglycans aggrecan, biglycan, and decorin. The maximum size of 
cartilaginous tissue produced was 7 mm in diameter and 0.5 mm in thickness, still too 
small for partial-thickness cartilage repair. These cell-based studies indicate some of the 
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disadvantages of collagen scaffolds. Collagen gels allow for uniform mixing of cells and 
matrix, and for extensive molding and shaping of tissue, but tend to be fragile until new 
matrix is laid down. Solid collagen scaffolds such as membranes or sponges exhibit 
greater initial mechanical strength, but at the cost of less flexibility in shaping and a 
greater risk of non-uniform cell seeding. Collagen remains a useful scaffold with which 




Hyaluronic acid (HA) is a polysaccharide that is naturally found both in the ECM of 
articular cartilage and in synovial fluid and is responsible for the high lubricity of the 
cartilage surface. It is composed of alternating residues of N-acetyl-D-glucosamine and D-
glucoronic acid. As with collagen, interest focused on HA as a potential scaffold for 
cartilage engineering is due to its intimate association with chondrocytes in vivo. Intra-
articular HA injection has been used to treat symptoms of osteoarthritis with very large 
world markets and sales, and enhances cartilage lubrication and exerts many biologic 
effects on cells. HA has been shown to have a stimulatory effect on chondrocyte 
production of type II collagen and proteoglycan (37).  HA also has many 
immunomodulatory properties. HA below < 50kDa it is considered low molecular weight 
(LMW), inflammatory HA, and at 103-104 kDa and greater it is anti-inflammatory (38). 
HA interacts with many cell receptors including RHAMM, CD44, and the immune 
related receptors TLR2 and 4, giving it the ability to impact inflammation and cell 
migration-both important aspects of wound healing (39). It is also thought that LMW HA 
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may provide a danger signal to immune cells to attract them to the site of tissue 
degeneration to aid in tissue debris clearance, which can damage tissue when occurring 
chronically (40). These properties make HA a highly dynamic and important molecule to 
include in scaffold designs, especially considering that HA makes up a significant part of 
the chondrocyte pericellular matrix (41) Clinical trials using HA to treat OA have found 
variable results in the efficacy of HA to reduce OA progression. More research on how 
variation in different HA products such as molecular weight and cross-linking affects 
clinical outcome is needed to optimize HA therapeutic effect (42). 
Extracellular Matrix as a biomaterial 
The ECM, which contains growth factors and structural components including 
collagens, proteoglycans, and elastins, has been used with great success in treating 
muscle and chronic non-healing wounds. Despite this, few studies have been done 
implementing ECM into cartilage defects, in part because of a concern for using 
xenogeneic materials as well as the relatively variable processing of ECM- there are no 
strict guidelines on what amount of cellular material should remain after decellularization 
(43, 44). However, a few groups have implemented xenogeneic materials into cartilage 
defects (45). One group used rabbit perichondrium in an articular cartilage defect in a 
sheep knee. After 12 weeks, new cartilage was formed and there was no immunologic 
reaction in the synovium (43). Another group implemented ECM particles in vivo to 
reduce OA progression in a rat model of OA (46).  Treatment with human amnion 
decellularized membrane resulted in attenuated cartilage degradation, as well as increased 
levels in MCP-1, which recruits monocytes. This suggests that ECM can reduce OA 
progression, potentially through modulation of immune cells (47). Some groups have 
cultured cells to create “cell-derived ECM scaffolds” to avoid the use of xenogeneic 
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ECM, however the scale process still needs to be increased (48). Due to the limited 
availability of “cell-derived ECM scaffolds,” the use of xenogeneic ECM should be 
explored further (44). 
Synthetic Scaffolds 
Bioscaffolds derived from natural materials are generally considered more favorable 
in terms of the biological response they can elicit from cells compared to synthetic 
scaffolds (49).  However, biological materials can be difficult to generate in large 
quantities with acceptable consistency, and often exhibit poor mechanical characteristics 
(35). Synthetic materials are generally less expensive than biologics and are created de 
novo and provide more precise control over the structural properties, mechanical 
properties, and rates of resorption with a great deal of batch-to-batch consistency (50). 
The most common synthetic polymers and traditional tissue engineering scaffolds are 
polyglycolic acid (PGA), polylactic acid (PLA), polyethylene oxide (PEO), and various 
derivatives and copolymers based on these entities including poly-di-lactic-co-glycolic 
acid (PLGA) (35). In general, these materials exhibit many beneficial properties for the 
production of engineered tissue: a high surface area to volume ratio if processed 
correctly, sufficient porosity to allow for nutrient and waste diffusion, the potential for 
surface modification, and the ability to control their degradation rate via selection and 
modification of their chemical composition (51). In particular, the ability to specifically 
control the rate of degradation is important for scaffold survival in vivo. First, the scaffold 
must provide sufficient mechanical strength when first implanted but should optimally 
degrade at the same rate as new tissue generation. If degradation is too rapid, then there is 
a risk of cell loss, scaffold failure, and inflammation and death of surrounding tissue due 
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to rapid release of acidic breakdown products (52, 53). Conversely, an overly slow rate of 
scaffold degradation would likely impede tissue incorporation. The question remains: 
how do we determine the replacement rate of the cartilage tissue? This depends on a 
number of factors including the scaffold itself, but more importantly, the age of the 
patient and the level of inflammation in the joint. Articular cartilage changes with age, 
including increased collagen crosslinking, decreased synthesis of type 2 collagen and 
aggrecan, and reduced tensile strength (54). Additionally, senescent cells contribute to the 
poor reparative abilities of aging cartilage. Senescent cells do not divide but instead cause 
chronic inflammation in the aging tissue (55). Chondrocytes can also become senescent, 
slowing down the rate of scaffold replacement with new cartilage, further impacting the 
rate of new tissue growth. 
Biological factors 
Growth factors, cytokines, protein gradients, cell-cell interactions, and ECM-cell interactions 
control cellular differentiation, migration, adhesion, and gene expression. How growth factors 
control cartilage development, maintenance, and changes during diseased states has been 
investigated intensively. The primary growth factor families that control cartilage homeostasis are 
the TGF-β superfamily, BMPs within the TGF- β superfamily, insulin-like growth factors (IGFs) 
and fibroblast growth factors (FGFs). The role of each of these factors in cartilage growth and 
homeostasis, as well as effects on stem cells, is varied and diverse. To briefly summarize, TGF-β 
and IGF generally exert anabolic effects on chondrocytes including inducing increased type II 
collagen and GAG synthesis, maintaining chondrocyte phenotype, and promoting chondrocyte 
proliferation, whereas FGF suppresses proteoglycan synthesis and encourages chondrocytes to 
take a fibroblast morphology (56). Despite TGF-β signaling generally maintaining chondrocyte 
phenotype and encouraging chondrocyte growth, TGF-β signaling is altered in OA, resulting in 
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deleterious effects (57). Most growth factor-only related approaches to preventing cartilage loss 
involve modulating either anabolism or catabolism of the cartilage tissue and/or inhibiting pro-
inflammatory cytokine signaling. Examples include intra-articular injection of TGF-β, 
interleukin-1β (IL-1β) inhibitors, and MMP13 inhibitors (58, 59). However, the diverse roles of 
growth factors cause difficulty in attempting to implement them in cartilage engineering. Some 
anabolic growth factors may cause osteophytes in OA, or do not induce a response in older cells, 
or may not be enough to combat the degratory enzymes present in a diseased joint (60).There are 
also additional signaling molecules, integrins, which are molecules that span the cell membrane 
and connect the cell cytoskeleton to the extracellular matrix (ECM). This allows the cell 
environment-including material stiffness and mechanical forces- to influence cell morphology, 
migration, and signal transmission (61).  
Growth factors can also be broadly administered to a cartilage defect via platelet rich 
plasma (PRP), an autologous blood product containing platelet-derived growth factors. 
PRP contains TGF-β1, IGF-1, VEGF, and PDGF (platelet derived growth factor). PRP 
can be made with or without leukocytes. The mechanism of how PRP coordinates an 
anti-inflammatory, proliferative, or remodeling response in cartilage is still unknown, but 
is thought to be due to stimulating cell proliferation, migration, and matrix synthesis (62, 
63). Despite lack of FDA approval, the components that form PRP are approved, and 
PRP has been used in cartilage defects clinically, in many cases in combination with 
microfracture or scaffolds (64). There are many proposed mechanism of action for PRP, 
including that the growth factors secreted by platelets are be responsible for at least part 
of the cartilage repair and pain relief, however, more research is needed to further define 
PRP’s mechanism of action (65). Once a mechanism is defined, it will be easier to 
optimize PRP for treatment of osteoarthritis.  
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Translation of cartilage tissue engineering 
Preclinical Translation 
There are many important aspects to consider in designing preclinical (“in vivo”) 
studies for translating engineered scaffolds/cell/peptide therapies including the clinical 
indication, animal, and disease model. The type of therapy will also dictate study design 
and approach. For example, initial studies for cell-seeded scaffolds often start with simple 
subcutaneous implantation to examine their ability to generate cartilaginous tissue in 
vivo. If these studies show that the in vivo environment and tissue scaffold is not hostile 
to the development of cartilage and osteochondral tissues, the therapy is then tested in the 
target tissue to determine therapeutic efficacy.  
The choice of animal model as well as the application of the material is crucial to 
successfully moving therapies to the clinic. For example, if an engineered cartilage 
construct is intended to fill articular cartilage defects, it is likely that the person receiving 
the cartilage construct will have osteoarthritis or some chronic inflammation. So, not only 
is the promotion of new cartilage formation and lack of rejection by the animal important, 
but as the presence of disease will have many implications on the success of the therapy, 
preclinical testing of materials needs to take the disease state into account. In the case of 
OA, there are several mouse as well as rat and guinea pig models of OA requiring either 
mechanical loading of the knee joint, transecting the ACL or meniscus, or injecting MIA 
(monoiodoacetate) to induce cartilage damage (66).  
Animal models still have room to improve. Many therapies, such as iNOS inhibitors 
and COX inhibitors, were shown to decrease cartilage lesions and osteophytes in separate 
OA animal models, but did not show clinical efficacy in humans (67). This problem may 
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be due in part to the fact that most preclinical testing is performed early in OA disease 
progression, however people treated clinically are in late stage OA. Additionally, animals 
used experimentally are generally young adults as opposed to the majority of OA 
patients, who are aging adults over 60 (67). Studies evaluating the biological differences 
in OA between young and old animals are needed to help advance the utility of animal 
models in screening therapies.  
Clinical Translation 
There are many different cartilage bioengineering therapies currently in clinical 
testing, with most therapies consisting of either scaffold alone or scaffold plus cells 
(MSCs or chondrocytes), mesenchymal stem cell only therapies, PRP injections, and 
viscosupplementation (68). Autologous chondrocyte implantation (ACI) is meant for 
localized cartilage injuries and applies the patient’s own expanded chondrocytes in 
solution to the defect under a surgically closed periosteal flap (16, 17). This allows the 
autologous articular chondrocytes to synthesize new cartilaginous matrix in the defect 
site. ACI is clinically approved (Carticel), but the clinical outcomes of the standard ACI 
methods have disadvantages including donor site morbidity, risk of leakage of 
transplanted chondrocytes, complexity of the surgical procedure (69), uneven distribution 
of the cell suspension in the transplanted site (70), periosteal hypertrophy (71), and 
dedifferentiation of the chondrocyte phenotype during in vitro monolayer culture (72, 
73). These problems prompted matrix-induced ACI (MACI), second-generation ACI to 
be developed. MACI involves applying cell-seeded constructs instead of cell suspensions 
for cartilage repair. Vericel MACI therapy has recently been approved clinically in the 
US by the FDA and is the first autologous cellularized scaffold approved in the US for 
the repair of cartilage defects. This MACI technique uses an implant with a bio-
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resorbable Type I / III collagen membrane with approximately 1,000,000 cells per square 
centimeter. This therapy has been found to improve KOOS score (Knee Injury and 
Osteoarthritis Outcome Score) more significantly than microfracture but have similar 
histological repair outcomes in phase three clinical testing (74).   
Variations of the MACI approach include a technology in which the in vitro 
chondrocyte expansion was performed using a 3D scaffold made from modified HA (75). 
The scaffold was then implanted into cartilage defects via a mini-arthrotomy or an 
arthroscopic approach. Their cohort includes 141 patients followed for 2–5 years. Their 
results appear impressive, with improvement in subjective symptoms reported in over 
90% of patients. Second-look arthroscopy was performed in 55 patients, and the cartilage 
repair was graded as normal or near-normal in over 95% of these patients. Biopsies were 
taken in 22 of these 55 patients, which revealed a hyaline appearance in 12 out of 22, 
with the remainder having a mixed or fibrocartilaginous appearance. Currently, 
Histogenics has the most advanced engineered cartilage therapy in the US. This MACI 
therapy, NeoCart, expands chondrocytes, after which they are seeded on a collagen 
scaffold that is matured in a bioreactor before implantation in a cartilage defect. Now in 
Phase III clinical testing in the US, results thus far demonstrate reduced pain, increased 
function, and imaging-confirmed defect filling with NeoCart treatment (76). 
Biomaterials alone are also being implanted in conjunction with microfracture or other 
autologous cell/tissue sources for focal cartilage repair to provide a simplified off-the-
shelf therapeutic. Various approaches have been developed to incorporate biomaterials 
with microfracture, e.g. using polymer scaffold combined with minced cartilage from a 
biopsy (77, 78), implanting collagen membranes microfracture (79), and applying 
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chitosan mixed with blood after microfracture (80, 81). These biomaterial-guided tissue 
repair methods may be more economical and provide an off-the-shelf therapy that is more 
efficacious than surgical intervention alone. 
Achieving integration of engineered tissue with host cartilage is still a troublesome 
problem for cartilage reconstruction, especially for long-term cartilage repair (82). 
Cartilage integration failure was very common and probably caused by a variety of 
factors, including limited chondrocyte mobility in the cartilage extracellular matrix, 
chondrocyte cell death at the wound edge, chondrocyte dedifferentiation in the 
engineered tissue, the type of biomaterial scaffold, and the origin and the stage of the 
cells used for cartilage tissue engineering. Corresponding solutions have been reported to 
enhance the construct including cartilage integration by pretreating the cartilage interface 
enzymatically to break down collagenous matrix (83, 84), inhibiting the chondrocyte 
death at the lesion edge (85), and using immature constructs instead of mature constructs 
(83). Recently, we developed a mechanically strong biological glue to bridge native 
cartilage with biomaterial scaffolds (86). This glue is based on chondroitin sulfate (CS), 
one of the major components of the cartilage ECM, functionalized with methacrylate and 
aldehyde groups to react chemically with the biomaterials and cartilage proteins. Using 
this glue, full integration was achieved in full-thickness chondral defects following 
marrow stimulation. Recent studies suggest that PRP can improve cartilage integration of 
explants (87, 88), suggesting that immunomodulation plays an important role in 
successful explant integration. 
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Current and Future Trends in Cartilage Engineering 
The tissue engineering techniques discussed above show great potential advantages 
over conventional surgical options and are being applied to clinical practice intensively 
(89). The ultimate aim of articular cartilage tissue engineering is to design an engineered 
tissue that can regenerate to hyaline cartilage with normal knee functions and integrate 
fully with the surrounding native cartilage. To date, no engineered tissue construct fulfills 
this criterion, and as such there is considerable ongoing work in various aspects of 
cartilage tissue engineering research from cell type, bioscaffold, biological factor, 
bioreactor, to tissue translation. It would be nearly impossible to summarize the vast body 
of this research in a single chapter, so the range of studies outlined above is necessarily 
only a brief summary of the past and current literature on selected topics. 
The recurring theme throughout much of the current literature is that the engineered 
tissue has the histological appearance and biochemical makeup of cartilage of varying 
stages of maturation. However, it has been reported that mechanically most of these 
constructs are inferior to native cartilage. As the basic techniques of chondrocyte, 
osteoblast, and MSC culture are elucidated, the focus shifts toward improving the 
mechanical properties of engineered tissues. One concern is that, in order to achieve 
complete reconstruction of cartilage defects, the transplanted tissue can initially have 
mechanical strength inferior to native cartilage temporally to allow the tissue to mature 
and integrate to the surrounding cartilage ultimately under the in vivo environment. It 
should be considered that a large gap still exists between the in vivo studies and in vitro 
testing and optimization for the clinical translation of engineered cartilage. The in vitro 
methods should be standardized to provide clear results to develop successful clinical 
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applications for cartilage tissue engineering (90). There are several important basic 
questions that remain to be answered. What are the optimal types, amounts, and timing of 
the growth factor milieu? Perhaps PRP will help answer this question after further 
characterization. Will small molecular drugs work effectively for cartilage tissue 
engineering since many biological factors are complex and exhibit delivery problems? In 
vitro models provide the isolated environment necessary to clearly define genetic 
programming and signaling pathways that are involved in chondrocyte maintenance, 
however fail to compensate for all the dysregulated signaling pathways in vivo which will 
ultimately dictate the success or failure of a bioengineered therapy. More pre-clinical 
models of cartilage defects need to be utilized to determine the impact of the host 
environment on bioengineered therapies.  
An overlooked aspect to cartilage engineering is the use of cytokines and manipulation 
of the immune cells that produce them. The immune system has typically been viewed 
only as being responsible for material rejection and tissue destruction, with immune 
suppression considered ideal. However, in light of recent work showing the importance 
of the innate and adaptive immune system in tissue repair, future work will most likely 
focus on modulating the immune system, not simply suppressing it.  
NSAIDs and corticosteroids continue to be used despite studies that have shown some 
adverse effects regarding articular cartilage metabolism.  Part of this is due to that the fact 
that these treatments help to manage patient pain, however medications for pain relief are 
often un-effective in the management of arthritis pain.  We need to develop better 
alternatives, particularly ones that do not broadly suppress the immune system like 
corticosteroids do. Harnessing macrophages and T cells for tissue regeneration would be 
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a logical strategy, considering that they already have many functions in tissue 
remodeling. Additionally, as T cell therapies are already used in other diseases such as 
cancer immunotherapy, they could be adapted for use in cartilage regeneration to guide 
macrophage polarization and direct the tissue repair process. 
Of course, there are many more questions and challenges that remain before the 
promise of tissue engineering is fully realized. The contributions of scientists in fields as 
diverse as cell/molecular biology, materials science, chemistry, and mathematics will be 
required in order to answer these questions. 
Approaches in osteoarthritis therapy: from biomaterials to immunology  
This dissertation details the application of several biomaterials, including ECM and a 
peptide-polymer, for OA treatment. The first segment details the use of porcine urinary 
bladder matrix in a post-traumatic mouse model of OA. The second segment details the 
use and optimization of a hyaluronic acid binding peptide in a post-traumatic mouse 
model of OA. These studies focus on the potential OA disease modifying activity of 
applying these therapies intra-articularly to the joint. The final segment of the dissertation 
details the study of immune cells in post-traumatic OA progression. This work was 
undertaken to better understand the role of these immune cells, particularly of Th17 cells, 
in OA progression. As suggested in this introductory chapter, the immune state of tissue 
can impact the regenerative abilities of biomaterials. Therefore, it is important to better 
understand exactly how these immune cells are altered in OA before we can tailor our 
biomaterial-based therapies to reduce disease progression. 
Tissues that play a role in OA progression besides cartilage are the synovium and 
subchondral bone marrow. It is important to take these tissues into account while trying 
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to repair cartilage because they contribute cells and cytokines which impact cartilage. It is 
known that there is often synovial inflammation in OA that can contribute to joint 
damage (91). Several immune cell types have been found in the synovium via 
immunohistochemistry in animal models of OA, including CD4+ T cells, CD8+ T cells, 
macrophages, and dendritic cells (92-95). In humans, T cells, B cells, NK cells, and 
dendritic cells have been identified in synovium via immunohistochemistry (95, 96). 
Despite these observations, no real initiative has been taken to further study the role these 
cells may have in the progression of OA, or how their modulation may lessen disease 
progression. 
Additionally, the subchondral bone is an important joint component that is remodeled 
during the course of OA, either before or concurrently with cartilage destruction (97). 
The subchondral bone marrow contains many cell types including stromal cells and stem 
cells for hematopoiesis, and lymphocytes including T cells and B cells originate from the 
bone marrow (98). It is also known that when the subchondral bone in OA is remodeled, 
this is accompanied by macrophage infiltration and osteoclast formation (99, 100). One 
group performed flow cytometry and identify inflammatory cells in the OA subchondral 
bone marrow (101). Despite the identification and apparent involvement of these cells in 
OA, the state of these subchondral bone marrow immune cells has not been investigated 
further in OA progression. In chapter 4, we will go further into detail on cells of the 
immune system and what is known about their role in arthritis as well as present our 
findings on altered immune cell populations in the mouse ACL transection model of post 










Chapter 1 Figures 
Figure 1. Revised approach to tissue engineering triad. 
 
Figure 1. Cells, growth factors, and immune cells/immune environment contribute to 
engineered cartilage regeneration. The immune system contributes inflammatory and 
anti-inflammatory signals, as well as antigen specific and non-specific recognition of the 
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Abstract 
Micronized porcine urinary bladder matrix (UBM) is an extracellular matrix biomaterial 
that has immunomodulatory and pro-regenerative properties. The objective of this study 
was to assess the ability of UBM to alter disease progression in a mouse model of post-
traumatic osteoarthritis (OA). Ten-week–old wild type C57BL/6 male mice underwent 
anterior cruciate ligament transection (ACLT) to induce OA. Two weeks after ACLT, 
UBM (50 mg/ml) or saline was injected into the mouse joint. At 4 and 8 weeks post-
ACLT, cartilage integrity was assessed using OARSI scoring of histology, pain was 
evaluated, and joints were harvested for quantitative RT-PCR analysis of cartilage-
specific and inflammatory gene expression. UBM-treated animals showed improved 
cartilage integrity at 4 and 8 weeks and reduced pain at 4 weeks compared to saline-
injected mice. Animals injected with UBM expressed higher levels of genes encoding 
structural cartilage proteins, such as collagen2α1 and aggrecan, as well as anti-
inflammatory cytokines, including interleukins 10 and 4. UBM decreased cartilage 
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degeneration in the murine ACLT model of OA, which may be due to reduced 
inflammation in the joint and maintenance of high expression levels of proteoglycans. 
Introduction 
Osteoarthritis (OA) is a prevalent degenerative musculoskeletal disease that results in 
both biological and mechanical dysfunction of the cartilage tissue that lines the surface of 
articulating joints. Between 2010 and 2012 alone, 52.5 million adults were diagnosed 
with OA in the U.S. (102). OA is characterized by a progressive loss of cartilage tissue, 
dysfunctional remodeling of the underlying bone, inflammation of the synovial 
membrane, and abnormalities in lubrication of the articular joint. Current therapies for 
OA are minimal and often palliative. Palliative options include non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroid injections to control pain; however, 
these pharmaceuticals do not slow or reverse disease progression. The primary 
therapeutic treatment for OA is end-stage joint replacement, such as total-knee 
replacement surgery. These surgeries are invasive, and as severity of OA is increasing in 
younger patients, the comparably short lifetime of knee joint replacements present a 
challenge (103). The ultimate goal for OA treatment is to find a disease-modifying 
osteoarthritis drug (DMOAD) that can promote tissue regeneration, reduce or stop the 
progression of OA, and ultimately promote regeneration of the lost tissue. There is a 
small number of promising DMOAD pharmaceuticals currently in clinical development 
that aim to modulate either anabolism or catabolism of the cartilage tissue, or inhibit pro-
inflammatory cytokine signaling. These therapies include intra-articular injection of an 
interleukin-1β (IL-1β) inhibitor and chondroitin sulfate (58). However, no DMOAD 




Owing to the dearth of therapeutic options for OA, there remains a critical need 
for new approaches for treating disease and rebuilding tissue. Biomaterials-based 
strategies may be an option for degenerative musculoskeletal bone and cartilage diseases, 
as synthetic hydrogels have improved disease score in rabbits with posttraumatic OA 
(104) as well as in goats and humans with focal cartilage defects (105). Treatment with 
biologics composed of extracellular matrix (ECM) is a regenerative medicine option for 
tissue reconstruction.  
Unlike synthetic polymeric materials, ECM scaffolds are composed of an intricate 
mixture of proteins, glycoproteins, and polysaccharides, which can be isolated by 
chemically and/or mechanically removing cells from various tissue sources. The ECM 
provides structural support for cells, binds to and sequesters growth factors, and plays 
important roles in cell adhesion and signaling via integrins (41). These properties make 
the ECM a biologically active scaffold that influences cell differentiation, proliferation, 
survival, polarity, and migration (106). ECM scaffolds derived from different tissues 
have distinct properties, as the structure and function of each tissue is highly specific. For 
example, while cartilage tissue has a relatively low ratio of cells-to-ECM and high 
collagen and proteoglycan content, brain tissue contains a much higher ratio of cells-to-
ECM, more secreted factors, and little collagen (107, 108). The ECM can also be 
chemically and physically processed into several biomaterial configurations, including 
injectable particulates. ECM derived materials manufactured from different tissues, such 
as urinary bladder and small intestinal submucosa, have applications ranging from burn 
wound treatment to urinary tract repair (109). Additionally, ECM has been used in a 
small animal model of  post-traumatic OA to reduce cartilage degeneration (47). 
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In this study, we are using particulate ECM as a biologic and immunomodulatory 
agent to advance OA therapy and cartilage tissue regeneration. We investigated an ECM 
biomaterial derived from porcine urinary bladder matrix (UBM), which maintains an 
intact basement membrane with high amount of collagens III and VII (110), elastic fibers, 
adhesive proteins, and glycoproteins (110). UBM has been shown to promote 
regeneration in soft tissue injury through a number of mechanisms. Remodeling UBM 
was shown to shift the local macrophage response in vivo towards a pro-healing, anti-
inflammatory phenotype (111), and recruits progenitor cell proliferation and 
differentiation after traumatic muscle injury in mice (112). UBM similarly promoted 
muscle repair in patients with volumetric muscle loss in a clinical study (113). UBM has 
also been applied clinically to chronic non-healing ulcers and has resulted in 
epithelialization of the ulcers with limited scar tissue formation (114, 115). Additionally, 
UBM was applied to complicated wounds not responding to conventional therapies with 
the result of epithelialization and successful skin grafting (116). UBM also facilitates soft 
tissue reconstruction in traumatic wounds by establishing a neovascularized soft tissue 
base (117).  
The physicochemical and immunomodulatory properties of UBM make it an 
attractive therapeutic for OA, as OA—previously regarded as a predominantly 
mechanical disease—is now thought to progress due to excessive inflammation, immune 
cell infiltration, and cytokine secretion (118, 119) (120). Only one other report has shown 
the use of ECM in a small animal model of  post-traumatic OA, but used human amnion 
ECM and has not shown evidence of the mechanism by which ECM helped reduce 
cartilage degeneration or shown functional pain reduction (47). We therefore tested the 
28 
 
effect of UBM on OA disease progression and tissue regeneration in rodents by injecting 
micronized UBM into a mouse model of post-traumatic OA, and by treating primary 
human chondrocyte cultures from OA cartilage in vitro. The results indicate a positive 
effect of UBM treatment on cartilage integrity in vivo, improved functional outcomes, 
and enhanced expression of several structural cartilage and anti-inflammatory genes. 
Methods 
Surgical Procedures: All procedures were approved by the Johns Hopkins University 
Animal Care and Use Committee (ACUC). OA was induced by anterior cruciate ligament 
transection (ACLT) (121) in 10-week-old male C57BL/6 mice from Charles River.  Two 
weeks after ACLT, a single 10-µL injection of either a phosphate-buffered saline (1X 
PBS, from Life Technologies) vehicle control or micronized UBM (~88% of the particle 
volume was under 20 μm and the D50 (median size) was 5.09 μm) suspended in 1X PBS, 
pH 7.2, 50 mg/ml, from ACell®, Inc., Columbia, MD) was administered to the joint 
space of the operated knee via a 30-gauge needle (n=13 animals for 4-week, n=8 animals 
for 8-week time point). The joint cavity was opened in the sham-group but the ACL was 
not transected. The study design is depicted in Fig. 1a. UBM particles were made using a 
Retsch CryoMill from Verder Scientific. A single steel ball (25 mm diameter) resides 
with the raw UBM sheet material during grinding. The chamber was kept cool via liquid 
nitrogen. Data on particle size distribution is in supplementary figure 2. 
Histological evaluation: After 4 or 8 weeks, animals were sacrificed, and mouse knees 
were fixed in 4% paraformaldehyde (PFA), decalcified for approximately 2 weeks in 
10% EDTA, then dehydrated and embedded in paraffin.  Seven-µm–thick sections were 
taken throughout the joint and stained for proteoglycans with Safranin-O and Fast Green 
(Applied biosciences) per manufacturer’s instructions. Osteoarthritis research society 
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international (OARSI) scores are based on blinded histological assessment the medial 
plateau of the tibia (n=4-7 per group) (122). 
Immunohistochemistry: Slides were de-paraffinized and treated with hyaluronidase 
(0.25% in Tris buffer) before staining for COL2 using Anti-Collagen II antibody 
(ab34712) from Abcam at 1:300 dilution (in 4% BSA/0.25% Triton X-100) followed by 
secondary staining with a biotinylated antibody and streptavidin-peroxidase conjugated 
enzyme using the Histostain-SP IHC kit, AEC, from ThermoFisher (cat. no. 959943) 
according to the manufacturer’s instructions (n=3). 
Gene expression analysis: Whole mouse joints were frozen in liquid nitrogen and 
homogenized using a sterile mortar and pestle (n=3-4). RNA was extracted using TRIzol 
reagent (Life Technologies) following the manufacturer's protocol. cDNA was 
synthesized using Superscript III reverse transcriptase (Life Technologies) following the 
manufacturer's protocol. Real-time RT-PCR was carried out using SYBR Green primers 
and a StepOnePlus Real-time PCR System (Life Technologies). Relative gene expression 
was calculated by the ΔΔCt method. The ΔCt was calculated using the reference genes 
β2-microglobulin (B2m) and β-actin (Bact).  ΔΔCt was calculated relative to the 
unoperated control group. The mouse specific primers used were the following: Bact 
forward, CCA CCG TGA AAA GAT GAC CC, Bact reverse, GTA GAT GGG CAC 
AGT GTG GG, B2m forward, CTC GGT GAC CCT GGT CTT TC, B2m reverse, GGA 
TTT CAA TGT GAG GCG GG, Acan forward, CGT TGC AGA CCA GGA GCA AT, 
Acan reverse, CGG TCA TGA AAG TGG CGG TA, Col2a1 forward, CCT CCG TCT 
ACT GTC CAC TGA, Col2a1 reverse, ATT GGA GCC CTG GAT GAG CA, Mmp13 
forward, GTC TTC ATC GCC TGG ACC ATA, Mmp13 reverse, GGA GCC CTG ATG 
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TTT CCC AT, Runx2 forward, GCC GGG AAT GAT GAG AAC TA, Runx2 reverse, 
GGT GAA ACT CTT GCC TCG TC, Il4 forward, ACA GGA GAA GGG ACG CCA T, 
Il4 reverse, ACC TTG GAA GCC CTA CAG A, Il10 forward, TCT CAC CCA GGG 
AAT TCA AA, Il10 reverse, AAG TGA TGC CCC AGG CA , Il6 forward, CCA GGT 
AGC TAT GGT ACT CCA GAA, Il6 reverse, GCT ACC AAA CTG GAT ATA ATC 
AGG A, IL1b forward, GTA TGG GCT GGA CTG TTT C, IL1b reverse, GCT GTC 
TGC TCA TTC ACG. 
Hind Limb Weight Bearing Assessment: Weight-bearing in mice was measured in the 
un-operated control animals and compared to ACLT animals receiving PBS control or 
UBM therapy using an incapacitance tester (Columbus Instruments). The percentage 
weight distributed on the ACLT limb was used as an index of joint discomfort in OA 
(121). The mice were positioned to stand on their hind paws in an angled box placed 
above the incapacitance tester so that each hind paw rested on a separate force plate. The 
force (g) exerted by each limb was measured. Three consecutive 3-second readings were 
taken and averaged to obtain the mean score (123). 
Hind Limb Responsiveness: Mice were placed on the hotplate at 55ºC. The latency 
period for hind limb response (jumping or paw-lick) was recorded as response time 
before surgery and at 2 and 4 weeks after surgery in all animal groups (121). Three 
readings were taken per mouse and averaged to obtain the mean response time for each 
time point. 
Human Chondrocyte Isolation and Cell Culture: Human chondrocytes were isolated 
from OA cartilage harvested from cadaveric sources (n = 3) from the National Disease 
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Research Interchange. Cartilage was minced to 1-mm3 pieces, rinsed 3x in 1X PBS, and 
suspended in 25 mL of collagenase media [DMEM with 5% FBS and 1.67 mg/mL type II 
collagenase] per every 10 mL of cartilage pieces, then placed on a shaker at 37ºC for 16-
18 hours. Cells were filtered through a 70-µm cell strainer, spun down at 1000 rpm for 10 
minutes, and rinsed 3x with PBS. Chondrocytes were plated in a 6-well plate with 
~250,000 cells/well in chondrocyte media ( high-glucose DMEM supplemented with 
10% FBS, 1% nonessential amino acids, 1% HEPES, 1% sodium pyruvate, 0.2 M L-
proline, 25 mg/mL ascorbic acid, and 1% pen/strep). After ~4 hours of attachment, 10 
ng/ml of IL-1 was added to the media and allowed to incubate for 16-18 hours before 
addition of UBM, which then incubated for 24 hours before cell isolation for PCR. ΔΔCt 
was calculated relative to the untreated control group that received only IL-1β. The 
following human specific primers were used: BACT forward, GCT CCT CCT GAG CGC 
AAG TAC, BACT reverse, GGA CTC GTC ATA CTC CTG CTT GC, B2M forward, 
GAG GCT ATC CAG CGT ACT CCA, B2M reverse, CGG CAG GCA TAC TCA TCT 
TTT, MMP13 forward, TGG TCC AGG AGA TGA AGA CC, MMP13 reverse, TCC 
TCG GAG ACT GGT AAT GG, ADAMTS5 forward, GAG GCC AAA AAT GGC TAT 
CA, ADAMTS5 reverse, GGC AGG ACA CCT GCA TAT TT, NF-kB forward, AAC 
AGA GAG GAT TTC GTT TCC G, NF-kB reverse, TTT GAC CTG AGG GTA AGA 
CTT CT, TNFα forward, CCT CTC TCT AAT CAG CCC TCT G, TNFα reverse, GAG 
GAC CTG GGA GTA GAT GAG, IL6 forward, GGC ACT GGC AGA AAA CAA CC, 
IL6 reverse, GCA AGT CTC CTC ATT GAA TCC, IL1β forward, GGA CAA GCT 
GAG GAA GAT GC, IL1β reverse, TCG TTA TCC CAT GTG TCG AA 
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Alamar Blue Assay: Human OA chondrocytes were plated at a density of 10,000 
cells/well in a 96-well plate and incubated at 37ºC until attachment occurred, after which 
10 ng/ml of IL-1 and varying concentrations of UBM were added to the media and 
allowed to incubate for 24 hours. Ten µL of Alamar Blue® reagent (ThermoFisher 
Scientific) was added directly into each well and the plate was incubated at 37ºC for 3 
hours protected from light. Absorbance was measured using a microplate reader every 
hour for 3 hours at a wavelength of 570 nm. Data were normalized to readings at 600 nm. 
These measurements were used to calculate percent of Alamar Blue reduced compared to 
control (cells with IL-1 but no UBM). 
UBM particle labeling and confocal microscopy: UBM particles were suspended in 
bicarbonate buffer (pH=8.3) and labeled with an Alexa Fluor-488 N-hydroxysuccinimide 
ester conjugate (Thermo Fisher) for 2 hours at room temperature. Excess dye was 
removed by washing several times with PBS via centrifugation. Fluorescent labeling and 
dye removal was confirmed by fluorescence measurements with a plate reader (BioTek 
Synergy 2). Labeled and un-labeled particles were added to human chondrocytes cultured 
on 1.5 mm thickness coverglass chamber wells (ThermoFisher Scientific) for 24 hours. 
Cells were then washed with PBS to remove unbound ECM and fixed with 4% 
paraformaldehyde for 20 minutes at room temperature. Cell membranes and nuclei were 
counterstained the CellMask Deep Red plasma membrane stain (Thermo) and DAPI, 
respectively, for 5 min. Entire cell volumes were imaged using a Zeiss LSM 710 confocal 
microscope with a 63X oil immersion objective and 0.3 um slice thickness. Three 
dimensional cell reconstruction was performed using IMARIS software (Bitplane).  
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Statistical Analysis: Statistical analysis was performed using a one-way ANOVA with 
Holm-Sidak multiple comparison correction in GraphPad Prism Software. For in vivo 
work, all groups were compared to each other. For in vitro work, each treatment was 
compared to the control group. P < 0.05 was considered significant. 
 
Results 
UBM injection reduces OA progression in mice 
The ACLT model of post traumatic OA was chosen for its reproducibility and its 
relevance to human injury; approximately 50% of people of who tear their ACL develop 
OA within 10-20 years (124). The mouse ACLT model develops OA about 4 weeks after 
injury (125). ACL-transected mouse knees were injected with UBM particles or saline at 
2 weeks post-ACLT and the effects on cartilage integrity and whole-joint inflammation 
were assessed at 4 and 8 weeks (2 and 6 weeks after therapy, respectively) (Fig. 1a). 
OARSI scoring, which is indicative of OA severity on a scale of 0 to 5 (0 is no cartilage 
degeneration, 5 is severe degeneration) revealed a statistically significant decrease in OA 
severity following UBM treatment group compared to saline controls at both 4 and 8 
weeks.  UBM particles reduced average disease scores from 3.2 to 1.4 at 4 weeks and 
from 3.7 to 1.9 at 8 weeks compared to saline alone. (Fig.1b). At 4 weeks, mice treated 
with the saline control exhibited proteoglycan loss as shown by diminished safranin-o 
staining (Fig. 1c; arrows) and cartilage lesions (Fig. 1c; stars) on their tibia. Injection of 
UBM in the synovial cavity decreased the severity of lesions and qualitatively increased 
the proteoglycan staining compared to the saline control (Fig. 1c). This effect was 
maintained even at 8 weeks post-injury, indicating a protective effect of UBM treatment 




UBM therapy decreases expression of inflammatory markers 
We next sought to characterize the osteoarthritic microenvironment after UBM 
treatment. As OA is a whole joint disease involving the cartilage and synovial tissue, 
inflammatory gene expression was evaluated in whole knee joint tissue using qRT-PCR. 
Cytokines thought to be involved in the pathophysiology of OA are the pro-inflammatory 
cytokines IL-1, tumor necrosis factor  (TNF-), and IL-6, which increase the 
production of matrix metalloprotease 13 (MMP-13), a collagenase that participates in 
cartilage degeneration (124). Macrophages are hypothesized to be important in OA and 
contribute to the expression of these cytokines; M1 polarized macrophages produce the 
pro-inflammatory cytokines IL-1β, IL-6, and IFNγ (126), whereas M2 polarized 
macrophages often produce the anti-inflammatory cytokines IL-10, IL-4, and IL-13.  
Gene expression of these inflammatory cytokines as well as cartilage catabolism 
and anabolism were evaluated in whole mouse joints at 4 and 8 weeks post-ACLT (Fig. 
2). At 4 weeks, joints treated with UBM demonstrated significantly increased expression 
of the structural genes Aggrecan (Acan, approximately 9-fold) and collagen 2α1 (Col2a1, 
13-fold) in addition to the anti-inflammatory genes Il4 (2.6 fold) and Il10 (5 fold) over 
un-operated control when compared to the saline control, which did not affect expression 
(Fig. 2, A and B). Additionally, the 4-week UBM treatment group reduced expression of 
the inflammatory cytokine Il1b compared to saline injections with 1.4 and 2.5-fold 
changes from unoperated mice, respectively. Conversely, expression of the pro-
inflammatory cytokine Il6 and enzyme Mmp13 were increased in the saline group as 
compared to un-operated wild type mice (3 fold and 5-fold, respectively), but not in the 
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UBM group. Runx2 expression was not affected by any treatment suggesting that there 
was no chondrocyte hypertrophy. This is consistent with the observed increase in ECM 
gene expression as chondrocyte hypertrophy is associated with negative cartilage 
remodeling, including decreased collagen and proteoglycan production and alkaline 
phosphatase secretion, allowing abnormal calcification of the articular cartilage to occur. 
At 8 weeks, joints treated with UBM demonstrated significantly increased 
expression of the anti-inflammatory gene Il10 (3.8 fold) compared to the saline control 
(no change) (Fig. 3). Aggrecan (Acan) also exhibited significantly increased expression 
in the UBM treated group compared to an age-matched normal control (2.2 fold). No 
other genes were affected by UBM injection, indicating that the anti-inflammatory effect of 
the UBM had resolved between 4-8 weeks post ACLT (Fig. 3). The maintenance of cartilage 
integrity observed at 8 weeks post ACLT and the sustained increase in Il10 and Acan 
expression suggests that the therapeutic effects of UBM may be mediated, at least in part, 
by these genes. 
To validate the finding of increased collagen 2α1 expression in UBM-treated 
mice, histological sections from each treatment group were stained for the collagen 2α1 
protein (COL2α1) (Fig. 4). Cartilage from UBM-treated mice at 4 weeks consistently 
stained more intensely for COL2α1 than the saline control cartilage. The 8-week UBM 
treatment group stained more intensely than the 8-week saline control despite not 
expressing significantly higher Col2a1 (as assayed by qPCR) (Fig. 3). This discrepancy 
could be due to the fact that collagen protein can be retained long after Col2a1 gene 
expression has diminished. 
UBM injection reduces pain in OA mice 
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After the majority of intra-articular cartilage is damaged from OA, severe pain arises 
from exposed nerve endings that were once protected by the dense cartilage. This is a 
hallmark of OA and can serve as a clinical endpoint for treatment trials. Thus, we 
determined if the UBM mediated improvement in cartilage structure (shown in Fig. 1a) 
correlated with a functional decrease in pain through hotplate and incapacitance testing 
(Fig. 5) (121). The UBM-treated groups at 4 and 8 weeks exhibited faster response time 
than saline treated mice with the hotplate test, on par with the healthy sham animals, 
which indicates decreased motor impairments compared to saline-injected mice (Fig. 5a). 
UBM-treated animals also demonstrated greater weight-bearing percentage on the 
operated limb at 4 weeks, indicating less functional impairment than saline-treated mice 
despite ACLT (Fig. 5b). At 8 weeks, however, weight-bearing percentage was not 
statistically different between the control (saline) group and UBM-treated animals. 
UBM decreased inflammatory marker expression in human OA chondrocytes 
Pro-regenerative gene expression within the mouse knee after UBM treatment led 
us to ask whether there was a biological effect of UBM on human OA chondrocytes. 2D 
culture is not a perfect model of what occurs in the knee joint; however, in vitro 
chondrocyte culture has been used to elucidate biological effects of therapeutics (123).  
To maintain OA conditions in vitro, primary human OA chondrocytes were 
cultured in the presence of IL-1 for 1 day prior to the addition of varying concentrations 
of UBM. We assessed the expression of several genes involved in OA progression after 1 
day of UBM exposure. Genes tested included the matrix degrading enzyme MMP13, the 
pro-inflammatory stress-related transcription factor NF-κB1 (nuclear factor kappa-light-
chain-enhancer of activated B cells), the aggrecan degrading enzyme ADAMTS5 (a 
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disintegrin and metalloproteinase with thrombospondin motifs 5), and the pro-
inflammatory cytokines TNF, IL6, and IL1. As chondrocytes are the cell type 
synthesizing aggrecan, a major structural component of cartilage, it is relevant to observe 
expression of ADAMTS5, the enzyme that degrades aggrecan. UBM induced a dose-
dependent response in most genes tested. The 100 ng/mL and 1000 ng/mL concentrations 
of UBM produced the most apparent reductions in inflammatory cytokine and matrix-
degrading enzyme expression, while the lowest concentrations (1 ng/ml, 10 ng/ml) had 
no beneficial effects (Fig. 6). The 1 μg/mL UBM dose lowered MMP13 compared to the 
control group (0.5 fold). There was an observed reduction of NF-κB1 and ADAMTS5 
expression by UBM treatment (by 0.4 and 0.6-fold, respectively), but did not reach 
statistical significance (p=0.054, 0.07, respectively). This trend of decreased 
inflammatory cytokine and matrix-degrading enzyme expression is similar to our findings 
in vivo. Additionally, the alamar blue assay was performed to confirm that UBM 
treatment is not toxic. There were no significant changes in percent reduction of alamar 
blue across the tested UBM concentrations. 
To determine how UBM may be directly interacting with chondrocytes in vitro, 
confocal imaging was performed 24 hours after adding 1 µg/ml or 100 ng/ml of 
fluorescently labeled UBM to chondrocyte media. Imaging revealed that human 
chondrocytes do not engulf UBM entirely but do appear to contact the surface of most 
particles (Fig. 6b).  
 
Discussion 
ECM biomaterials, such as UBM, are an attractive therapy for OA disease modification 
due to their regenerative capabilities in animal models and in humans (47, 113). UBM is 
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used clinically for several different applications including management of trauma wounds 
(127), chronic non-healing wounds (103), and esophageal reinforcement in gastrectomy 
(106). Because OA does not yet have a viable treatment, and UBM has shown promise in 
other musculoskeletal defects and degenerative diseases, the possibility of UBM to treat 
OA was tested here in a mouse model and in human primary cells. Injection of UBM into 
the synovial cavity of mice with ACLT-induced OA improved the articular cartilage 
integrity 4 and 8 weeks after injury and reduced pain compared to saline-treated controls. 
At 4 weeks, the expression of structural genes (Acan, Col2α1) and anti-inflammatory 
cytokines (IL4, IL10) were significantly increased compared to controls. Accordingly, 
UBM treatment decreased the expression of the pro-inflammatory cytokine Il1 in vivo in 
mice and the remodeling enzyme MMP-13 in vitro in human OA chondrocytes. While 
chondrocytes exhibited reduced expression of matrix degrading and pro-inflammatory 
genes, it is unclear to what extent particles would interact with them directly. 
Alternatively, the synovium is more permeable to particle passage meaning that 
synoviocytes may be more likely to encounter particles in synovial fluid; their response 
to UBM is worthy of further investigation (128). 
These results are consistent with the theorized role of the immune response in OA 
disease progression. Previously, Finnegan et al. described a role of IL-10, an important 
anti-inflammatory cytokine in collagen-induced arthritis. The severity of arthritis in IL-10 
knockout  (Il10-/-) mice was substantially greater than that in wild type or Il10+/- 
(heterozygous) mice, indicating a role for IL-10 in moderating disease severity (129). In a 
separate study on rabbits with OA, IL-10 cDNA delivered ex vivo to rabbit synoviocytes 
and then injected intra-articularly was able to reduce cartilage breakdown (130). These 
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reports are consistent with our findings of IL-4 and IL-10 expression accompanied by 
cartilage protection. 
The observed high expression of type II collagen and proteoglycan genes is most 
likely beneficial in maintaining cartilage integrity (123). Tesche et al. found that type II 
collagen was synthesized by the remaining healthy chondrocytes in OA, but not by the 
fibroblast-like chondrocytes that produce an abnormal matrix (131, 132). Salminen et al. 
noted that articular chondrocytes are capable of producing type 2A procollagen, but near 
the margins of cartilage defects, chondrocytes were metabolically inactive and 
surrounded by a noncollagenous matrix, which probably contributed to the loss of 
cartilage integrity (133). These findings point to a dynamic in which proteoglycan 
expression occurs in OA and may actually help maintain cartilage integrity; it is only 
when collagenases and aggrecanases exceed this repair capability that the cartilage shifts 
to production of an abnormal matrix, leading to a loss of cartilage integrity resulting in a 
defect. Because inflammatory cytokines encourage the expression of catabolic enzymes, 
perhaps control of the inflammation in the knee using biomaterials such as UBM may 
help shift the balance in the favor of anabolic genes and maintain the cartilage integrity. 
UBM may additionally work by directly encouraging deposition of chondrocyte-derived 
matrix; ECM materials are known to induce deposition of host-derived matrix after being 
degraded by the host (58). Enhanced matrix deposition by UBM was supported in the 
mouse joints by increased Col2α1 and Acan expression at the 4-week time point. At the 
8- week UBM treatment time point, it is plausible that collagen protein was retained well 
after gene expression had diminished. 
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 In our study, the heightened expression of Il-10 and Il-4 suggests that there may 
be type-2 immune cells (M2 macrophages and Th2 T cells) infiltrating the joint at higher 
numbers in the UBM-treated animals than in saline controls. M1 macrophages and Th1 T 
cells are known to lead to type 1, pro-inflammatory immune response (126) while M2 
macrophages and Th2 T cells are anti-inflammatory and can lead to matrix 
deposition(134). Because the dysregulation of these cell types leads to immune-mediated 
pathologies, it is reasonable that balancing these cell types can help modify OA disease 
progression (134). Future studies may elucidate how immune cell populations change 
over the course of OA and how they change with UBM therapy. Additionally, gene 
expression of these separate cell populations can be examined to identify which immune 
cell populations are responsible for the increases in IL-4 and IL-10 expression. 
 In conclusion, injection of UBM in the intra-articular space lessens cartilage 
degeneration in an ACLT mouse model of OA, and also induces a dose-dependent pro-
regenerative, anti-inflammatory gene expression profile in human OA chondrocytes. This 
therapeutic effect may be due to the reduced inflammation in the joint and maintenance 
of high expression levels of proteoglycans, which together help to retain normal cartilage 
and limit tissue degradation. To further validate the use of UBM as an OA therapeutic, 
additional animal models should be tested (135). Today, there are no FDA-approved 
disease modifying OA drugs available, making comparisons of UBM to current 
therapeutic options difficult. However, reduction in OA-associated pain could be 
compared to NSAIDs, viscosupplements or biological injections such as platelet-rich 




M. Frisk for editing. Okhee Jeon for histology scoring. The Wilmer NEI-NIH funded 
Imaging Core, the Wilmer Pooled Professor Fund, and Rhonda Grebe for confocal 
expertise. ACell Inc. for supplying UBM and providing financial support for the study 






















Chapter 2 Figures 
Figure 2.1 UBM treated mice show reduced OA progression 
 
Figure 1: UBM treated mice show reduced OA progression. A. Overview of 
treatment. Mice were injected with 50mg/ml of UBM (10um-20um particles) 2 weeks 
after ACL transection and euthanized at 4 and 8 weeks post ACL transection. B. OARSI 
scores from the medial plateau of each animal. C. Representative images from each 










Figure 2.2 UBM injection decreases expression of inflammatory markers 
 
Figure 2. UBM injection decreases expression of inflammatory markers. Quantitative 
PCR on whole joint samples at 4 weeks post UBM injection. A. Cartilage related genes. 
UBM treated mice increased Aggrecan (Acan) and Collagen 2α1 (Col2a1) expression 
compared to saline treatment. Additionally, expression of Matrixmetalloproteinase 13 
(Mmp13) and RUNX2 (Runx2) are not statistically significantly increased over wild type. 
B. Immune related genes. UBM treated mice increased IL-4 (Il4) and IL-10 (Il10) 
expression and decreased IL-1β (Il1b) expression compared to PBS control mice. 








Figure 2.3 UBM injection decreases expression of inflammatory markers 
 
Figure 3. UBM injection decreases expression of inflammatory markers. Quantitative 
PCR on whole joint samples at 8 weeks post UBM injection. A. Cartilage related genes. 
UBM treated mice increased Aggrecan (Acan) expression compared to WT treatment. B. 











Figure 2.4 Collagen 2α1 Staining 
 
Figure 4. Collagen 2α1 Staining. Slides close to the representative image used for OARSI scoring 
for each joint were stained with col2α1 to verify the PCR results of increased col2α1 gene 
expression. Qualititatively, UBM treated animals at 4 weeks post-surgery have more intense col2α1 
staining compared to the saline control group. The 8 week UBM group is improved compared to 












Figure 2.5 UBM treatment reduces pain 
 
Figure 5: UBM treatment reduces pain. UBM treated mice have reduced pain at 4 weeks 
compared to PBS control mice. A. UBM treated mice have reduced time on the hotplate compared 
to PBS control mice, indicating less pain in the operated leg.  B. UBM treated mice have increased 
weight placed on the operated leg as measured by incapacitance testing, also indicating less pain 















Figure 2.6 UBM decreased inflammatory markers in human primary chondrocytes 
 
Figure 6: UBM decreased inflammatory markers in human primary chondrocytes A. Gene 
expression data from in vitro human chondrocytes exposed to 10ng/ml of IL-1β and 1ng/ml-1μg/ml 
of UBM (n=3). B. Confocal imaging of 1ug/ml UBM (left) and 100ug/ml UBM (right) 24 hours 
after addition into cell culture medium. Red=cell membrane (seen at 50% transparency) , 
Blue=nucleus, Green=UBM. UBM particles appear to be almost entirely encapsulated by the cell 










S. Figure 2.1 UBM can reduce chondrocyte toxicity in the presence of IL-1β 
 
Supplementary figure 1: UBM can reduce chondrocyte toxicity in the presence of IL-1β. 
Alamar blue cell toxcity test. Primary human chondrocytes were cultured in10ng/mL IL-1 β and 
each experimental condition for 24 hours before performing the Alamar Blue assay. Absorbance 
values were taken at 570nm and 600nm 1,2, and 3 hours after addition of alamar blue and percent 













S. Figure 2.2 UBM particle size distribution. 
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Hyaluronic acid (HA) is found naturally in synovial fluid and is utilized therapeutically to 
treat osteoarthritis (OA). Here, we employed a peptide-polymer cartilage coating 
platform to localize HA to the cartilage surface for the purpose of treating post traumatic 
osteoarthritis. The objective of this study was to increase efficacy of the peptide-polymer 
platform in reducing OA progression in a mouse model of post-traumatic OA without 
exogenous HA supplementation. The peptide-polymer is composed of an HA-binding 
peptide (HABP) conjugated to a heterobifunctional poly (ethylene glycol) (PEG) chain 
and a collagen binding peptide (COLBP). We created a library of different peptide-
polymers and characterized their HA binding properties in vitro using quartz crystal 
microbalance (QCM-D) and isothermal calorimetry (ITC). The peptide polymers were 
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further tested in vivo in an anterior cruciate ligament transection (ACLT) murine model 
of post traumatic OA. The peptide-polymer with the highest affinity to HA as tested by 
QCM-D (~4-fold greater binding compared to other peptides tested) and by ITC (~3.8-
fold) was HABP2-8-arm PEG-COLBP. Biotin tagging demonstrated that HABP2-8-arm 
PEG-COLBP localizes to both cartilage defects and synovium.  In vivo, HABP2-8-arm 
PEG-COLBP treatment and the clinical HA comparator Orthovisc® lowered levels of 
inflammatory genes including IL-6, IL-1B, and MMP13 compared to saline treated 
animals and increased aggrecan expression in young mice. HABP2-8-arm PEG-COLBP 
and Orthovisc® also reduced pain as measured by incapacitance and hotplate testing. 
Cartilage degeneration as measured by OASRI scoring was also reduced by HABP2-8-
arm PEG-COLBP and Orthovisc®. In aged mice, HABP2-8-arm PEG-COLBP 
therapeutic efficacy was similar to its efficacy in young mice, but Orthovisc® was less 
efficacious and did not significantly improve OARSI scoring. These results demonstrate 
that HABP2-8-arm PEG-COLBP is effective at reducing PTOA progression. 
Key Words: Osteoarthritis, hyaluronic acid, peptide-polymer, anterior cruciate ligament, 
cartilage, hyaluronic acid binding peptide 
 
1. Introduction 
Osteoarthritis (OA) is a degenerative joint disease that results in both biological and 
mechanical dysfunction. It is estimated to affect 40% of people over the age of 70 (137). 
OA is characterized by a progressive loss of cartilage tissue, remodeling of the 
underlying bone, inflammation of the synovial membrane, and abnormalities in 
lubrication of the articular joint. Lubrication is facilitated by molecules in the synovial 
fluid and at the cartilage surface including lubricin and hyaluronic acid (HA). Moreover, 
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engineered or repair cartilage lacks the typical surface and lubrication properties of 
normal tissue. Current therapies for OA primarily target symptoms and fail to modify 
disease progression. Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain 
but do not alter disease progression. Steroids are also effective at relieving pain but cause 
cartilage damage and chondrotoxicity when used for extended periods of time (138). 
While a few potential disease modifying drugs are in clinical testing, the lack of currently 
available options leaves joint replacement surgery as the only therapeutic choice for 
treating end stage disease.  
One therapeutic approach for managing OA is to supplement the synovial fluid. Synovial 
fluid is an important constituent of a functional knee joint which acts as a biochemical 
repository, supplies nutrients to articular cartilage, promotes chondrocyte proliferation 
and differentiation, and reduces friction at direct cartilage-cartilage surface interactions in 
the articular joint (139-143). Cartilage lubrication is facilitated by molecules in the 
synovial fluid and at the cartilage surface including the proteoglycan lubricin and large 
glycosaminoglycans including hyaluronic acid (HA). High molecular weight (HMW) HA 
(>1,000 kDa) is the primary contributor to the viscoelasticity of synovial fluid. HMW HA 
is degraded into proinflammatory low molecular weight (LMW) HA by hyaluronidases in 
the course of aging and inflammation, including during OA progression, and results in 
further disease progression. Reduced amounts of HMW HA in synovial fluid lead to 
decreased synovial fluid viscosity (144-146), which increases friction between 
articulating cartilage surfaces, leading to increased cartilage deterioration (147). 
Introducing HMW HA back into synovial fluid of arthritis patients, known as visco-
supplementation, improves joint lubrication and reduces patient pain (148). Visco-
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supplementation is a well-established treatment option; however, it has limited longevity 
and requires frequent, repeated administrations [7]. This challenge has prompted several 
groups to consider biomaterials-based approaches to augment joint lubrication. Roberts 
describes the use of HA binding peptides in hydrogels containing HA. These hydrogels 
enhance retention of HA compared to control gels without HA binding peptide (149). 
Additionally, there are other investigators pursuing synthetic lubricants for cartilage 
regeneration. One group employed a lubricating multiblock bottlebrush polymer 
mimicking lubricin on mica surfaces and showed that it extended wearless friction with 
the addition of fibronectin. In another study, bottle-brush copolymers were synthesized to 
mimic the structure and function of lubricin; these polymers reduced friction relative to 
denuded cartilage plugs (150, 151).  Despite the current research aimed to aid in 
lubrication, supplementing synovial fluid remains a popular approach to treating OA due 
to the many biological and mechanical properties of increased HA in the synovial fluid, 
as well as the ease and minimal invasiveness of the procedure.  
Supplementing HA in the joint may temporarily increase viscoelasticity, however it also 
likely has additional biological effects in the articular joint that have not yet been fully 
elucidated. In any case, HA is not as effective at cartilage lubrication if it is not localized 
to the cartilage surface (152). Lubricin tethers HA to the joint surface in healthy joints;  
however, lubricin is reduced after trauma and in OA disease (153, 154). Therefore, we 
developed a therapy to aid in HA localization and retention to the cartilage surface. We 
previously developed a biomimetic system in which an HA-binding peptide (HABP) is 
non-covalently bound to the cartilage surface through a heterobifunctional poly(ethylene 
glycol) (PEG) chain and a collagen binding peptide (COLBP) (26). The COLBP anchors 
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the construct to exposed type II collagen in the cartilage, bringing any HA bound by the 
HABP moiety of the construct close to the cartilage surface. We demonstrated  that this 
technology enhanced HA retention in vivo and cartilage lubrication in vitro (26). Here, 
multiple peptide formulations were synthesized and evaluated for HA binding efficacy 
and OA treatment. HABPs that possess different binding properties, referred to here as 
HABP1, 2, and 3, were tested. HABP1 and HABP2 are synthetic HABPs found by phage 
display (155). HABP2 has homology to the hyaluronan mediated motility receptor 
(RHAMM) and HABP3 has homology to link protein (149, 156). Several formulations 
were synthesized using these peptides conjugated to linear or 8 arm PEG formulations to 
determine the optimal formulation of the peptide-polymer conjugate. When implemented 
in a model of post-traumatic OA, administration of the peptide-polymer binding system 
alone reduced the expression of inflammatory factors and cartilage degradation. 
2. Methods         
2.1 Overview of experimental design 
 Peptide-polymer formulations with different HABPs (HABP1, sequence 
GAHWQFNALTVR, HABP2, sequence STMMSRSHKTRSHHV, and HABP3, 
sequence RYPISRPRKRC) and different PEG shapes (linear, 8 arm) were tested to 
optimize in vitro binding to HA and screened in vivo for therapeutic efficacy. HABP2-8-
arm PEG-COLBP was selected for more in-depth testing of tissue localization in vivo 
against the control groups: HABP2-8-arm PEG, 8-arm PEG-COLBP, and HABP2-8-arm 
PEG-scrambled COLBP. The therapeutic efficacy of HABP2-8-arm PEG-COLBP was 
then compared in young and aged mice to the control groups 8-arm PEG-COLBP, 
HABP2-linear PEG-COLBP, and the clinical HA Orthovisc®. The ranges in peptide 
concentrations used throughout each animal study are listed here. For the specific 
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concentrations used in each figure, please refer to the figure legends: HABP1-linear 
PEG-COLBP (10-20mg/mL), HABP2-linear PEG-COLBP (25-50mg/mL), HABP3-
linear PEG-COLBP (50mg/mL), HABP1-8-arm PEG-COLBP (50mg/mL), HABP2-8-
arm PEG-COLBP (25mg/mL) and 8-arm PEG-COLBP (25mg/mL). For biotin tagged 
studies, all peptides were injected at 25mg/mL. 
2.2 Peptide-PEG conjugation 
 HABP2-PEG (3.4 Da)-COLBP, as well as individual peptides HABP1-3 and COLBP, 
were purchased from Synpeptide (Shanghai, China). For the formulations conjugated to 
linear PEG, hetero-bifunctional PEG was purchased with NHS on one end and a 
maleimide group on the other. The amine group on the N terminus of the HABPs reacted 
with NHS on linear PEG, and the thiol group at the C terminus of COLBP reacted with 
the maleimide group on linear PEG. For the 8-arm PEG formulations, eight-arm PEG-
maleimide (MAL) was purchased from Jenkem (Dallas, Texas). To create 8-arm PEG 
conjugated to HABP2 and COLBP, cysteine-containing HABP2 and COLBP 
(SynPeptide) reacted with 8-arm PEG-MAL at a molar ratio of 1:4:4 (8 arm PEG: 
HABP2: COLBP) in MES buffer (pH 6.0) for 4h followed by a dialysis against water 
(MWCO ~3400 Da) and lyophilization. For 8-arm PEG-COLBP, the reaction mixture 
had a ratio of 1:8 (8-arm PEG: COLBP). Peptide sequences can be found in S. Table 1. 
2.3 QCM-D (quartz crystal microbalance with dissipation monitoring) 
Gold sensor surfaces were coated with biological substrates in situ using either HA-thiol 
(100 μg/ml) or type II collagen fibrils (40 μg/ml). Compositions of HABP (100 μg/ml) 
were applied at a flow rate of 24 μl/min at 37°C in PBS (n=3) [3].  
2.4 ITC (Isothermal Titration Calorimetry) 
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 Twenty kDa Hyaluronic acid was diluted to a concentration of 0.1 mM- 0.4 mM and 
dialyzed against a buffer containing 100 mM MES pH 7.1. Peptides were diluted to 0.07 
mM- 0.2mM in 100 mM MES pH 7.1. ITC experiments were carried out at 26°C with a 
high-precision VP-ITC titration calorimeter system (Microcal Inc., CA). Ten microliters 
of the HA solution were added every 400 seconds to the cell containing 1.5 ml of HABP2-
8-arm PEG-COLBP. The heat of binding was obtained by integrating the calorimetric 
signal. The first injections were excluded from the analyses. Data were analyzed using 
Origin 5.0 (Microcal Software, Inc., Northampton, MA). Details of the analyses are 
presented in the Results section. 
2.5 Surgical Procedures 
All procedures were approved by the Animal Care and Use Committee at Johns 
Hopkins University School of Medicine. A murine model using C57/BL6 male mice 
was applied. OA was induced by anterior cruciate ligament transection (ACLT) as 
previously described (121, 157) in adult (10 weeks old) or aged (56 weeks old) mice 
(n=5-10). Briefly, the sham operation consisted of exposing the knee joint by a medial 
capsular incision, which cut the patellar tendon, and skin closure with sutures after 
irrigation with saline. For the ACLT surgery, after opening the joint capsule, the ACL 
was transected with micro-scissors under a surgical microscope. Two weeks after ACL 
transection, a single 10 uL intra-articular injection of either saline or specified treatment 
was administered to the operated knee via a 30-gauge needle. On week 4 post ACLT, the 
mice were euthanized, and joints were collected for gene expression quantification or 
histological assessment.  
2.6 Histological evaluation 
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 Mouse knees were fixed in 4% PFA, decalcified for 10-14 days in 10% EDTA, 
dehydrated, and embedded in paraffin.  Sections were taken at 7 µm throughout the joint 
and stained for proteoglycans with safranin-O and fast green. Osteoarthritis Research 
Society International (OARSI) scores, which are a measure of cartilage damage, were 
determined by a blinded scorer and based on a representative image taken from the 
medial plateau of the tibia unless specified otherwise (n=4-7) (122). OARSI scoring for 
aged mice was performed on medial and lateral tibial plateaus. The OARSI scores 
presented are an average of the lateral and medial scores (n=3-5).  
2.7 Gene expression analysis 
 Whole mouse joints were removed and snap frozen in liquid nitrogen and homogenized 
using a sterile mortar and pestle (n=3-4). RNA was extracted using TRIzol reagent (Life 
Technologies, Carlsbad, CA) following the manufacturer's protocol. cDNA was 
synthesized using Superscript III reverse transcriptase (Life Technologies) following the 
manufacturer's protocol. Real-time PCR was carried out using SYBR Green primers and 
a StepOnePlus Real-time PCR System (Life Technologies). Relative gene expression was 
calculated by the ΔΔCt method. The ΔCt was calculated using the reference genes β2 
microglobulin and β actin.  ΔΔCt was calculated relative to the un-operated control 
group. Gene expression fold change values for aged mice were calculated relative to the 
saline treated ACLT group. Statistical analysis was done with a one-way anova. The 
mouse specific primers used were the following: Bact forward, CCA CCG TGA AAA 
GAT GAC CC, Bact reverse, GTA GAT GGG CAC AGT GTG GG, B2m forward, CTC 
GGT GAC CCT GGT CTT TC, B2m reverse, GGA TTT CAA TGT GAG GCG GG, 
Acan forward, CGT TGC AGA CCA GGA GCA AT, Acan reverse, CGG TCA TGA 
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AAG TGG CGG TA, Col2a1 forward, CCT CCG TCT ACT GTC CAC TGA, Col2a1 
reverse, ATT GGA GCC CTG GAT GAG CA, Mmp13 forward, GTC TTC ATC GCC 
TGG ACC ATA, Mmp13 reverse, GGA GCC CTG ATG TTT CCC AT, Runx2 forward, 
GCC GGG AAT GAT GAG AAC TA, Runx2 reverse, GGT GAA ACT CTT GCC TCG 
TC, Il4 forward, ACA GGA GAA GGG ACG CCA T, Il4 reverse, ACC TTG GAA GCC 
CTA CAG A, Il10 forward, TCT CAC CCA GGG AAT TCA AA, Il10 reverse, AAG 
TGA TGC CCC AGG CA , Il6 forward, CCA GGT AGC TAT GGT ACT CCA GAA, 
Il6 reverse, GCT ACC AAA CTG GAT ATA ATC AGG A, IL1b forward, GTA TGG 
GCT GGA CTG TTT C, IL1b reverse, GCT GTC TGC TCA TTC ACG. 
2.8 Incapacitance Assessment 
Weight bearing (WB) of mice from the un-operated control, saline control, and treatment 
groups was measured using an incapacitance tester (Columbus Instruments, Columbus, 
OH). The percentage weight borne on the ACL transected limb was used as an index of 
joint discomfort in OA (121). The mice were positioned to stand on their hind paws in an 
angled box placed above the incapacitance tester so that each hind paw rested on a 
separate force plate. The force (g) exerted by each limb was measured. Three consecutive 
three second readings were taken and averaged to obtain the mean score (n=5-10) (123). 
2.9 Hotplate Analysis 
Mice were placed on the hotplate at 55oC. The latency period for hind limb response 
(jumping or paw-lick) was recorded as response time before surgery and at 2 and 4 weeks 
after surgery (n=5-10) (121). A longer response time indicates greater pain in the 
operated limb. 
2.10 Radioactive tagging and imaging studies 
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The radioactively tagged peptide, 111ln-DOTA-PEG-COLBP (MW:2364.31) was custom 
synthesized. 111In was purchased from Nordion (Ontario, Canada).  In a solution of 
111InCl3 [51.8 MBq (1.4 mCi)], 11 nmol of PEG-COLBP-DOTA (3.5 µl from a stock of 
3.4 mM) and 20 µl 0.2 M sodium acetate buffer (pH 4) were added and incubated at 65°C 
for 1 h.  The resulting 111In-DOTA-PEG-COLBP was incubated with 
ethylenediaminetetraacetic acid (EDTA) at a final concentration of 10 mM for 5 min to 
chelate unbound 111In and then subsequently purified on a PBS pre-equilibrated Zeba spin 
desalting column (Thermo Scientific).  Radiochemical purity and stability of 111In-
DOTA-PEG-COLBP were tested by instant thin-layer chromatography (ITLC) using 
EDTA (10 mM) solution as a mobile phase.  After purification the overall radiochemical 
yield and purity was ≥ 98% with specific activity > 3. 7 MBq (0.1 mCi)/nmol.  The 
peptide concentration was determined using a NanoDrop spectrophotometer (Thermo 
Scientific). 
 
Indium-111 tagged PEG-COLBP was injected into mouse knees (n=5) and imaged using a 
preclinical U-SPECT+ single-photon emission computed (SPECT) system from MILabs 
(Utrecht, The Netherlands) fitted with a high sensitivity collimator with 0.6 mm resolution. 
For each mouse, SPECT imaging data of the knee were acquired at the following time 
points: 5, 10, and 15 minutes, and 1, 3, 6 and 24 hours. The SPECT images were analyzed 
using AMIDE, a medical image analysis software. The image pixels were correlated to μCi 
based on a calibration factor. The radioactivity within a region-of-interest over the knee 
was plotted against time and two separate half-lives were determined: a distribution half-
life and an elimination half-life. Elimination half-life corresponds to the kinetics of drug 
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elimination from the body, and elimination half-life of the PEG-COLBP in the knee (based 
on uCi content during time period from 3 to 24 hour) is on average 33 h (standard deviation: 
20 h).  
2.11 Peptide-polymer biotin tagging 
Biotin-PEG (2000 Da)-thiol was purchased from Jenkem (Dallas, Texas). The peptides 
modified with biotin are the following: HABP2-8-arm PEG-COLBP, HABP2-8-arm 
PEG, 8-arm PEG-COLBP, and HABP2-8-arm PEG-scrambled COLBP. Peptides were 
modified with biotin by conjugating 8-arm PEG-MAL with thiolated HABP2, thiolated-
COLBP and Biotin-PEG-thiol at a ratio of 1:3:3:2 in an MES buffer (pH 6.0). In a similar 
procedure, a scrambled version containing HABP2-8 arm PEG-scrambled COLBP was 
obtained. Biotin-labeled 8-arm PEG-COLBP was obtained by reacting 8-arm-PEG-MAL 
and biotin-PEG-thiol with thiol-COLBP at a ratio of 1:4:4 (8-arm PEG: COLBP: Biotin-
PEG), while 8-arm PEG-HABP was obtained by reacting the mixture with thiol-HABP. 
All peptide-polymer samples were dialyzed against distilled water (MWCO 3400 Da) 
followed by lyophilization.  
2.12 Immunohistochemistry 
Biotin tagged peptide was visualized via immunohistochemistry by applying streptavidin-
peroxidase conjugated enzyme and AEC chromogen using the Histostain-SP IHC kit, 
AEC, from ThermoFisher (cat. no. 959943) according to the manufacturer’s instructions. 
2.12 Statistical analysis 
For in vitro binding assays, statistical analysis was performed using one-way ANOVA 
with Tukey’s multiple comparison test in GraphPad Prism Software. Each group was 
compared to each other. For in vivo work, statistical analysis was performed using one-
way ANOVA with Dunnett’s multiple comparison test in GraphPad Prism Software. 
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3.1 Peptide-polymer reduces cartilage degeneration without HA supplementation 
HABP1-linear PEG-COLBP was tested for the ability to reduce OA progression without 
HA supplementation. The peptide-polymer was injected with and without additional HA 
and compared to HA only treatment group (S. Fig. 1A). At 4 weeks post ACLT, both 
HA+ peptide-polymer, as well as peptide-polymer alone, significantly reduced expression 
of the matrix metalloproteinase MMP13 to approximately healthy levels, in contrast to 
the saline control (which was increased 5-fold over healthy). HA+ peptide-polymer and 
peptide-polymer also decreased average expression of IL-6 to healthy levels, however 
this did not reach statistical significance (p=0.07 and p=0.08, respectively). The HA only 
group was similar to the saline group in IL-6 expression. Peptide-polymer reduced TNFα 
to approximately healthy levels, however this did not reach statistical significance 
(p=0.07).  HA did not have any effect on TNFα expression (S. Fig. 2). Meanwhile, 
treatment with HA, peptide-polymer, and HA+ peptide polymer reduced cartilage 
degeneration as measured by OARSI scoring (S. Fig. 1B-C). These results demonstrate 
that HA-binding peptide-polymer is therapeutic even without addition of exogenous HA. 
3.2 HABP hyaluronic acid binding characterization  
After proof of concept efficacy validation for OA treatment, a library of peptide-polymer 
formulations was synthesized and screened to determine optimal binding capacity and 
therapeutic efficacy without exogenous HA supplementation. Three HABPs were 
combined with linear or 8-arm PEG to create the library of formulations. HABP and 
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COLBP sequences are listed in S. Table 1 (149, 155, 156, 158, 159). COLBP binding to 
type II collagen was confirmed with QCM-D (S. Fig. 3).  
HA binding to the various HABP formulations was quantified by quartz crystal 
microbalance with dissipation monitoring (QCM-D). Specifically, HA was thiol-
immobilized onto a QCM-D chip surface and different HABP formulations were added. 
The resulting decrease in frequency is a measure of increased mass on the surface of the 
chip, and in this experiment, a measure of peptide binding to HA. The HABP constructs 
were established to bind to immobilized HA (Fig.1A). HABP1 and 2 bound HA with the 
highest affinity (Δ frequency of ~1 and 2.3 Hz, respectively), while HABP3 had no 
detectable binding (HABP3 not displayed, Δ frequency <0.5 Hz). As HABP3 had the 
lowest affinity, it was excluded from further analysis. Binding of HABP1 and HABP2 
when conjugated to linear or 8-arm PEG was then evaluated (Fig. 1A). Conjugation to 
linear PEG reduced the average Δ frequency of HABP1 from 1 to ~0.5 Hz but did not 
significantly impact HABP2 peptide binding to HA (Δ frequency ~ 3 Hz). Conjugation to 
8-arm PEG significantly enhanced the binding of HABP2 to HA by approximately four-
fold (Δ frequency of 16 Hz), most likely by increasing the avidity of the peptide. 
However, conjugating HABP1 to 8-arm PEG ablated HA binding, suggesting conjugation 
interfered with the hydrophobic binding mechanism of HABP proposed by Mummert 
(155) (Fig. 1a). 
Next, the HA binding constant of the peptide-polymer formulation with the greatest 
binding capacity from the QCMD studies was determined. Isothermal calorimetry (ITC) 
was used to determine the efficacy of HABP2-8-arm PEG-COLBP binding to HA and 
was compared to binding of HABP2 alone and conjugated to the linear PEG formulation. 
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The binding constants were calculated and HABP2-8-arm PEG-COLBP bound HA with 
the highest affinity (Ka=5.9E5 M (+/- 1.06E5)), followed by HABP2-linear PEG-COLBP 
(Ka=1.53E5 M (+/- 7.06E3)), and lastly HABP2 (Ka=1.09E5 M (+/- 5.57E3)) (Fig. 1B, 
for detailed ITC plots see S. Fig. 4).  
3.4 Localization of optimized peptide-polymer in vivo  
Indium labeled linear PEG-COLBP was injected into the knees of 5 individual mice to 
determine the lifetime of PEG-COLBP and imaged using a U-SPECT system (0.6 mm 
resolution). For each mouse, images of the knee were acquired at the following time 
points: 5, 10, and 15 minutes, 1, 3, 6, and 20 hours (example images are in S. Fig. 5). The 
elimination half-life, corresponding to the kinetics of drug elimination from the body, 
was 33hrs for linear PEG-COLBP (+/- 20 hrs) (Fig. 2A).  
3.5 HABP2-8 arm PEG-COLBP localizes to degenerated cartilage, synovium, and 
subchondral bone 
The tissue specific retention of the peptide-polymer with optimal HA binding, HABP2-8 
arm PEG-COLBP, after OA induction was investigated. Biotin labeled peptide-polymers 
(defined in Fig. 2), were injected into joints 2 weeks post ACLT and mice were sacrificed 
10 minutes, 1 hour, 3 hours, and 24 hours post injection to observe peptide-polymer 
localization.  
At 10 minutes and 1-hour post injection, all peptide-polymer constructs localized to 
synovium, cartilage defect sites, and bone marrow (S. Fig. 6-7). Peptide-polymer also 
penetrated healthy cartilage, however it localized to damaged cartilage more strongly 
than to healthy cartilage. At 3 hours post injection, all peptide-polymers continued to 
localize to synovium and cartilage defects but exhibited less intense staining of the 
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synovium (Fig. 2B). At 24 hours post injection, the peptide-polymers exhibited different 
staining. The only staining observed for 8-arm PEG-COLBP 24 hours post injection was 
at cartilage defect sites, while 8-arm PEG-HABP only localized to synovium (S. Fig. 
8A). Meanwhile, HABP2-8-arm PEG-COLBP localized to cartilage defects and 
synovium (Fig. 2C), and HABP2-8-arm PEG-scrambled COLBP staining (not shown) 
was too variable to make a conclusion. Peptide-polymer did not evenly distribute to all 
defect areas, which may be due to limiting amounts of peptide-polymer. Additionally, a 
biotin only control was cleared 1-hour post injection, indicating that the observed 
peptide-polymer localization at 1,3, and 24 hours was not due to non-specific binding of 
biotin (S. Fig. 8B). 
3.6 HABP2-8-arm PEG-COLBP reduces OA progression 
Pilot studies confirmed that OA treatment with peptide-polymer with and without HA 
showed similar results. Therefore, the peptide-polymer was studied alone in the following 
in vivo studies. In a screen of multiple peptide-polymers, most formulations, including 
HABP1-linear PEG-COLBP, HABP2-linear PEG-COLBP, HABP3-linear PEG-COLBP, 
and HABP2-8-arm PEG-COLBP, improved cartilage structure after ACLT injury as 
determined by OARSI scoring (S. Fig. 9A-B). Among these formulations, HABP2-8 arm 
PEG-COLBP most significantly improved OARSI score compared to saline treatment 
(OARSI score=0.83).  
These in vivo results, together with the in vitro HA binding results, confirm that HABP2-
8-arm PEG-COLBP is the optimal peptide in terms of HA binding and reduction of OA 
progression. Therefore, HABP2-8-arm PEG-COLBP was studied further for validation of 
its in vivo efficacy and comparison to the clinically used visco-supplement Orthovisc®. 
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Treatment groups were included to control for (1) the size of the PEG linker (linear vs 8 
arm), (2) a peptide-polymer formulation without HABP2 (8-arm PEG-COLBP), and (3) 
the number of injections. Orthovisc® (OV) was included as a clinical benchmark control 
for pain reduction (160), and, as it is a high molecular weight HA, it is likely a good 
control for reducing the pro-inflammatory cytokines IL-6 and IL-1B.  
A single injection of the optimal formulation, HABP2-8-arm PEG-COLBP, reduced 
expression of inflammatory markers (Fig. 3D). HABP2-8-arm PEG-COLBP reduced IL-
6 expression from saline levels (~3-fold increased over healthy joints) down to healthy 
expression. It also reduced IL-1B from saline levels (~2.5-fold increase over healthy) to 
~1.1 fold over healthy and it reduced MMP13 from saline levels (~5-fold increase over 
healthy) to ~1.5 fold over healthy (Fig. 3E). HABP2-8-arm PEG-COLBP also increased 
aggrecan expression to ~6 fold over healthy joints (Fig. 3D). HABP2-8-arm PEG-
COLBP decreased pain as measured by both incapacitance testing and hot plate analysis. 
It increased weight bearing from ~75% weight bearing on the ACLT leg to almost full 
recovery (~97% weight bearing on ACLT leg) and reduced hotplate reaction time from 
saline levels (~8 s) to approximately healthy levels (~6.3 s). HABP2-8-arm PEG-COLBP 
also reduced cartilage deterioration as measured by OARSI scoring in the post-traumatic 
mouse OA model (Fig. 3A and B, OARSI avg=1.33). Two injections of HABP2-8-arm 
PEG-COLBP did not result in an increased therapeutic effect compared to a single 
injection, and efficacy in terms of gene expression (IL-6, 1.1 fold, IL-1B, 1.4 fold, and 
MMP13, expressed 1.6 fold over healthy), pain reduction (weight bearing ~97.6% and 
hot plate reaction time ~6.2s), and cartilage integrity (OARSI avg=1.64) were similar to 
that of a single injection of HABP2-8-arm PEG-COLBP (S. Fig. 10). Similarly, the other 
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treatments tested, Orthovisc®, HABP2-linear PEG-COLBP, and 8-arm PEG-COLBP, also 
reduced pain as measured by incapactiance and hot plate testing, resulting in weight 
bearing averages of 91%, 95%, and 94.6%, respectively, and hot plate measures of 6.6s, 
7.3s, and 5.8s, respectively (Fig. 4C and S. Fig. 10C). These groups additionally 
decreased expression of IL-6, IL-1B, and MMP-13 from saline levels to approximately 
healthy levels but did not significantly increase aggrecan expression (Fig. 3D and S. Fig. 
10D-E). Consistent with the observed gene expression and pain reduction conferred by 
these treatments, similar efficacy in reducing OARSI score was observed in the 
Orthovisc® (OARSI avg= 1.7), HABP2-linear PEG-COLBP, (OARSI avg = 1.9) and the 
8-arm PEG-COLBP (OARSI avg =1.58) groups (Fig. 4A-B and S. Fig. 10A-B). OARSI 
averages of the peptide-polymer treated groups at 4 weeks post ACLT (ranging from 
~1.5-2) were also compared to OARSI scores of untreated mice 2 weeks post ACLT (on 
average ~1.6) to determine the amount of cartilage damage taking place after peptide-
polymer injection. The similar OARSI scores suggest that peptide-polymers prevent 
cartilage degeneration from progressing but do not reverse it (S. Fig. 11).  
3.7 HABP2-8-arm PEG-COLBP reduces OA progression in aged mice  
The treatments tested in young mice were not significantly different from one another in 
terms of impact on OA progression with one treatment in the murine PTOA model. To 
better differentiate treatment group efficacy, HABP2-8-arm PEG-COLBP and control 
treatments were implemented in aged mice, which already have degeneration and provide 
a harsher environment for peptide-polymer testing. To mimic upper middle age, HABP2-
8-arm PEG-COLBP was tested in 15 month old mice (161).  
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HABP2-8-arm PEG-COLBP was injected into aged mice and compared to saline, 
Orthovisc®, and 8 arm PEG-COLBP. Although no statistically significant changes were 
observed, only HABP2-8-arm PEG-COLBP treatment decreased average MMP13 
expression to ~0.6-fold of the saline group. Similarly, only HABP2-8-arm PEG-COLBP 
decreased average IL-6 and IL-1B expression (Fig. 4D, each ~0.6-fold of the saline 
group, not significant). Neither Orthovisc® or 8 arm PEG-COLBP altered joint gene 
expression. Weight bearing was increased from ~75% weight bearing on the ACLT leg to 
almost full recovery in the HABP2-8-arm PEG-COLBP group (~100%, equal weight on 
both legs), however hotplate reaction time was similar to ACLT animals (~7.8 s). Similar 
pain reduction was also observed in the Orthovisc® (~90% weight bearing, ~7.5 s hot 
plate), but 8-arm PEG-COLBP did not reduce pain (~87% weight bearing, 7.5 s hot plate) 
(Fig. 4C). Only injection of HABP2-8-arm PEG-COLBP significantly reduced cartilage 
deterioration in the aged post-traumatic mouse OA model (Fig. 4A and B, OARSI 
avg=1.83, p=0.044). 8-arm PEG-COLBP reduced the average OARSI score to 2 
(p=0.07), while the average Orthovisc® OARSI score was 2.66.  
4. Discussion 
Disease modifying therapeutics for OA that could replace or augment HA visco-
supplementation are attractive as HA visco-supplementation is controversial. Some 
reviews claim that the patient benefit of intra-articular HA does not provide clinically 
relevant therapeutic benefit when compared to saline placebo treatments due to too small 
of an increase in the magnitude of effect in HA treated groups over placebo (162). 
Another frequent criticism is the heterogeneity of the effectiveness in pain and functional 
relief between studies (163). Additionally, HA products have different molecular weights 
and some are crosslinked; which makes it difficult to assess HA efficacy among different 
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clinical studies (164). Crosslinked HA has become popular due to its increased longevity, 
however crosslinking HA sacrifices some of the bio-compatibility of HA (165, 166). 
Some crosslinked HAs such as Synvisc induce inflammation and exhibit immunogenicity 
(165). In an extreme case, Synvisc-one caused systemic inflammatory polyarthritis after 
injection (167). Our HA binding technology could avoid these adverse events by 
enhancing HA longevity without the need for HA crosslinking. As demonstrated by the in 
vivo data presented, our technology could also be used alone without exogenous HA with 
comparable benefit to HA supplementation. However, as HA concentrations are reduced 
in the synovial space following injury, additional HA supplementation may further 
enhance HA binding technology efficacy in preventing OA progression. 
To test the ability of our HA binding technology to reduce OA progression, we employed 
the anterior cruciate ligament transection (ACLT) model of post traumatic OA. This 
model was chosen for its reproducibility and its relevance to human injury; 
approximately 50% of people of who tear their ACL develop OA within 10-20 years 
(124). When our peptide-polymers were implemented in this mouse model, all groups 
were efficacious in reducing OA progression. We hypothesized that this could be due in 
part to the young age of the mice, and that aged mice might be less responsive to 
treatment, aiding in observation of differences in therapeutic efficacy between treatments. 
One reason to utilize aged mice for this purpose is because the estimated incidence of 
symptomatic knee OA diagnosis is highest among adults age 55-64 (168). Mice in the 
range of 10-15 months are considered middle aged (with 15 months considered upper 
middle aged). Additionally, there are studies demonstrating that there is impaired 
regeneration during late middle age compared to youth in humans as well as in mice, 
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indicating that this is an important factor to account for in vivo studies (169-171). 
Accordingly, we implemented the peptide-polymers in a harsher, aged mouse model of 
OA. This enabled observation of different therapeutic effects between groups that were 
not observed in young mice. In this study, Orthovisc® reduced pain but did not reduce 
disease progression in the aged mice, which is also observed clinically, supporting the 
use of this aged mouse model.   
The biotin tagged peptide-polymer study demonstrates the ability of peptide-polymer to 
effectively localize at cartilage lesions. HABP2-8-arm PEG-COLBP localized to both 
cartilage and synovium 24 hours post injection, however the only staining observed for 8-
arm PEG-COLBP 24 hours post injection was at cartilage defect sites, suggesting the 
specificity of the COLBP for exposed cartilage ECM at cartilage lesions. The presence of 
HABP2-8-arm PEG at cartilage defects 3 hours post injection suggests that HABP can 
bind exposed HA in the cartilage. These results suggest that these formulations can be 
utilized as a delivery mechanism to target therapeutics to areas of cartilage damage or 
synovial membrane inflammation. 
The HA binding technology likely binds and concentrates endogenous HA from the 
synovial fluid to the cartilage surface to enhance lubrication. It is also possible that HA 
binding technology modulates some of HA’s many biological properties. LMW HA has 
pro-inflammatory effects while HMW HA has many anti-inflammatory functions (38). 
Some of the anti-inflammatory properties of HMW HA include inhibiting macrophage 
phagocytosis, preventing monocyte recognition of tumor cells via blocking CD44, 
promoting regulatory T cell proliferation via crosslinking the CD44 receptor, and 
inhibiting angiogenesis (172-174). HA injected intra-articularly can also decrease TNFα 
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and IL-8 expression (175). HA binding technology could potentially enhance these anti-
inflammatory functions by localizing HA to damaged areas where HMW HA is most 
needed. LMW HAs (<200kDa) cause macrophages and other cells to produce 
proinflammatory cytokines through receptors including CD44 and TLR2 (176, 177). HA 
binding technology could be binding LMW HA and preventing binding of LMW HA to 
other pro-inflammatory receptors such as TLR2/4. Previous studies have also 
demonstrated that HABP2 blocks HA signaling through RHAMM, resulting in reduced 
inflammation and fibrosis in skin wounds (156). Likewise, our study indicates that HA 
binding technology can modulate the expression of inflammatory genes in the joints of 
aged mice, unlike the HMW HA Orthovisc® or 8-arm PEG-COLBP groups. Although 
HMW hyaluronic acid reduces inflammation in many in vitro and in vivo animal studies, 
aged animals are rarely used to study therapeutics, limiting the translational relevance of 
these studies. Aged animals are better predictors of therapeutic outcome in age related 
diseases, and should be used in more small animal models for screening therapies (178).  
5. Conclusion 
In summary, we demonstrate that HA binding technology can be implemented after a 
trauma to slow further degeneration of the cartilage tissue without additional HA 
supplementation. Additionally, HABP2-8-arm PEG-COLBP could be conjugated to other 
drugs for targeted delivery to damaged areas of cartilage in vivo. Future studies in a larger 
animal model should be conducted to determine whether the therapeutic ability of 
HABP2-8-arm PEG-COLBP supplemented with HA will be enhanced over that of 
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Chapter 3 Figures 
Figure 1. HABP hyaluronic acid binding characterization 
 
Figure 1. A. QCMD frequencies of peptides binding to thiol-immobilized hyaluronic acid, n=3. i. 
HABP moieties and COLBP moieties available. ii. Cartoon example of peptide conjugated to 
linear peg. iii. Example of peptide conjugated to 8 arm peg. In sum, binding of HABP1, HABP2, 
HABP3, HABP1-linear PEG-COLBP, HABP2-linear PEG-COLBP, HABP1-8-arm PEG-
COLBP, and HABP2-8-arm PEG-COLBP were determined with QCMD. B. Binding constants of 
HABP2, HABP2-linear peg-COLBP, and HABP2-8-arm peg-COLBP to HA as determined by 






Figure 2. Localization of optimized peptide-polymer in vivo 
 
Figure 2. A. Peptide residence time in the joint. All peptide-polymer formulations were injected 
at 25mg/ml. Radioactively labeled linear PEG-COLBP was injected intra-articularly to determine 
half-life, n=5. The elimination half-life, corresponding to the kinetics of drug elimination from 
the body, was 33 h for linear PEG-COLBP (+/- 20 h). B and C. Biotin labeled peptide 
localization profiling. HABP2-8-arm PEG, 8-arm PEG-COLBP, HABP2-8-arm PEG, and 
HABP2-8-arm PEG-scrambled COLBP were biotin tagged and compared for tissue localization. 
Right image is safranin-o staining, left image is IHC (biotin tagged peptide stains brownish-red). 
B. 3 h post injection. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, 
and subchondral bone. Scrambled COLBP and HABP only (no COLBP) shows some absorption 
to the degenerated cartilage surface, probably due to interactions with HA in the cartilage. C. 24 




Figure 3. HABP2-8-arm PEG-COLBP reduces OA progression 
 
Figure 3. Only one intra-articular injection of each treatment was given unless otherwise 
specified. Orthovisc®, HABP2-linear PEG-COLBP, 8-arm PEG-COLBP, HABP2-8-arm PEG-
COLBP, and two injections of HABP2-8-arm PEG-COLBP were implemented in this study (for 
HABP2-linear PEG-COLBP and two injections of HABP2-8-arm PEG-COLBP group results, 
please see S. Fig. 10). All peptide-polymer formulations were injected at 25mg/ml. A. 
Representative images from the medial tibial plateau of each treatment group. Safranin-O staining 
(red) was used to visualize the cartilage proteoglycans. B. OARSI scoring demonstrates reduced 
cartilage degeneration in most treatment groups, n=6-7. The group with the most significant 
reduction in OA score was HABP2-8-arm PEG-COLBP, p=0.008. C. Pain testing, n=12. D and E. 







Figure 4. HABP2-8arm peg-COLBP reduces OA progression in aged mice 
 
Figure 4. Only one intra-articular injection of each treatment was given unless otherwise 
specified. HABP2-8-arm PEG-COLBP, 8-arm PEG-COLBP, and Orthovisc® were implemented 
in aged mice. All peptide-polymer formulations were injected at 25mg/ml. A. Representative 
images from the medial tibial plateau of each treatment group. Safranin-O staining (red) was used 
to visualize the cartilage proteoglycans. B. OARSI scoring demonstrates reduced cartilage 
degeneration with HABP2-8arm peg-COLBP treatment, p=0.044, n=3. C. Pain testing, n=6. 
Orthovisc® and HABP2-8arm peg-COLBP reduced pain as measured by incapacitance testing, 








Supplementary Table 1. Peptide sequences 
Peptide Name Sequence 
HABP1 GAHWQFNALTVR (Mummert) 
HABP2 STMMSRSHKTRSHHV (Tolg) 
HABP3 RYPISRPRKRC (Goetinck) 
COLBP WYRGRLC  




















S. Fig. 1 Peptide-polymer reduces cartilage degeneration without HA supplementation 
 
S. Figure 1. A. Mice were ACL transected and treated with either 20mg/mL HA, 10mg/mL 
HABP1-linear PEG-COLBP (HABP1 in figure), or HA+HABP1-linear PEG-COLBP two weeks 
post ACLT. B. HABP1-linear PEG-COLBP alone was able to confer a reduction in OA 
development via OARSI scoring, representative Safranin-O stained images  are in C. 












S. Figure 2. Peptide alone can modulate inflammatory cytokine expression 
 
S. Figure 2. HABP1-linear PEG-COLBP (HABP1 in figure) alone reduces MMP13 expression as 
















S. Figure 3. QCMD frequency and dissipation plots demonstrating COLBP binding to collagen 
 
S. Figure 3. Step 1 is baseline of the gold chip. Step 2 is the baseline after addition Col II. Step 3 
is the baseline after addition of specified peptide.  Dips in frequency indicate peptide binding to 
















S. Figure 4. Assessment of HABP2 binding to HA with ITC 
 
S. Figure 4. HA was loaded into the injector of the ITC machine and injected into a cell 
containing HABP2, HABP2-linear PEG-COLBP, or HABP2- 8-arm PEG-COLBP.  
A. 0.4mM HA into 0.2mM HABP2.  Ka=1.09E5 (+/- 5.57E3), Kd=9.17E-6 
B. 0.4mM HA into 0.2mM HABP2-linear PEG-COLBP, Ka=1.53E5 (+/- 7.06E3), 
Kd=6.53E-6 
C. 0.1mM HA into 0.07mM HABP2-8-arm PEG-COLBP, Ka=4.56E5 (+/- 5.91E4), 
Kd=2.19E-6 











S. Figure 5. Example U-SPECT images after intra-articular injection of 111In labeled PEG-
COLBP 
 
S. Figure 5. Images are rendered in AMIDE. Blue circles represent the ROI taken for analysis of 
signal intensity at the site of injection (the knee joint). Sagittal views of the 3 dimensional image 
analyses are shown here. ROI location changes due to the different position of the mice in 
imaging chamber at each time point. A. 5 minutes post injection. B. 1 h post injection. C. 3 h post 














S. Figure 6. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, and 
subchondral bone 
 
S. Figure 6. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, and 
subchondral bone. HABP2-8-arm PEG, 8-arm PEG-COLBP, HABP2-8-arm PEG, and HABP2-8-
arm PEG-scrambled COLBP were biotin tagged and compared. Images above are from knees 10 















S. Figure 7. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, and 
subchondral bone. 1-hour post injection. 
 
S. Figure 7. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, and 
subchondral bone 1-hour post injection. 
 
S. Figure 8. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, and 
subchondral bone. 24 hours post injection. 
 
S. Figure 8. HABP2-8-arm PEG-COLBP localizes to degenerated cartilage, synovium, and 





S. Figure 9. HABP2-8-arm PEG-COLBP reduces OA progression 
 
S. Figure 9. The following peptide-polymer formulations were tested for in vivo OA reduction: 10 
and 20  mg/mL HABP1-linear PEG-COLBP, 50 mg/ml HABP2-linear PEG-COLBP, 50 mg/ml 
HABP3-linear PEG -COLBP, 50 mg/mL HABP1-8 arm PEG -COLBP, and 25 mg/mL of 
HABP2-8-arm PEG -COLBP (10 µL each). Concentrations were based on the maximum 
solubility of each construct in saline. A. Representative images from the medial tibial plateau of 
each treatment group. Safranin-O staining (red) was used to visualize the cartilage proteoglycans. 
B. OARSI scoring demonstrates that HABP2-8arm peg-COLBP treatment most significantly 












S. Figure 10. HABP2-8-arm PEG-COLBP reduces OA progression 
 
S. Figure 10. All peptide-polymer formulations were injected at 25mg/ml. A-B. OARSI scores 
and representative images. Left: representative images from the medial tibial plateau of each 
treatment group. Safranin-O staining (red) was used to visualize the cartilage proteoglycans. 
Right: OARSI scoring demonstrates reduced cartilage degeneration in most treatment groups. C. 










S. Figure 11. Polymer-peptides halts OA progression 
 
S. Figure 11. Week zero is healthy joint OARSI score, 2-week measurements are from 2 week 
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Abstract 
It has been suggested that IL-17 may play a role in OA because of its observed presence 
in human OA tissue. However, the cellular sources of IL-17 and its impact on 
osteoarthritis have not been investigated. In this study, in-depth cell phenotyping revealed 
that the cell types responsible for IL-17 secretion in OA include γδ T cells, ILCs, and 
CD4 T cells. Local inguinal lymph nodes also had altered IL-17 levels. We then 
investigated the possible link between senescent cells, which are involved in OA 
pathogenesis, and Th17 cells along with their associated cytokines in osteoarthritis. 
Senescent cells were found to support Th17 polarization in vitro and eliminating 
senescent cells with IP and IA injections of senolytic in aged mice decreased IL-17 
expression and reduced OA progression. Additionally, systemic senolytic treatment 
increased the CD4/CD8 systemic ratio in aged mice back up to young mouse levels. 
Anterior cruciate ligament transection (ACLT) in IL-17Rα-/- mice also resulted in 





Osteoarthritis (OA) is a painful degenerative disease that destroys joint tissue, with an 
estimated lifetime risk of about 40% in men and 47% in women (137, 179). A primary 
cause of OA is joint instability leading to tissue damage, most commonly through tearing 
the anterior cruciate ligament (180-182). OA is characterized by a progressive loss of 
cartilage tissue, remodeling of the underlying bone, inflammation of the synovial 
membrane, and abnormalities in lubrication of the articular joint. Current therapies for 
OA primarily target symptoms and fail to modify disease progression. Non-steroidal anti-
inflammatory drugs (NSAIDs) can reduce pain but do not alter disease progression, and 
in fact can cause cartilage damage and chondrotoxicity when used for extended periods 
of time (138). While a few potential disease-modifying drugs are in clinical testing, the 
lack of currently available options leaves joint replacement surgery as the only 
therapeutic choice for treating end stage disease.  
OA is a multifactorial disease that both the immune system and aging contribute to 
pathologically. Little is known how these two factors influence the disease progress, 
however senescent cells appear to accumulate with ageing and are likely a causative 
factor in OA development (157). Senescence is a cell status wherein the cells are in 
permanent cell cycle arrest. Senescence is commonly controlled by the p53 pathway and 
pRB pathway. The p53 mediated DNA damage response activates gene expression of 
p21, and the pRB pathway triggers nuclear protein p16 response (183). Cells undergoing 
senescence adapt multiple phenotype changes and acquire a profile termed the 
senescence-associated secretory phenotype (SASP). Senescent cells (SnCs) influence 
their resident tissue microenvironment and local immune system through their 
inflammatory secretome. SnCs are observed in tissue trauma sites and accumulate with 
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ageing (184). SnCs’ complex interactions with tissue and the immune system are reported 
to multiple disease types. Their phenotype changes based on their activation pathways, 
local tissue environment, and their phenotype evolves over time (185). Senolysis 
selectively clears SnCs through activating apoptosis pathways. Previous research 
indicates senolysis could elongate life span and delay age-related disease (186, 187). 
The immune system is also important in the response to tissue damage. Tissue 
damage initiates a cascade of local and systemic immune events that attract immune cells 
into the damaged tissue to initiate host defense and tissue repair. The immune system 
contributes to tissue repair through multiple mechanisms including scavenging debris and 
dead cells, recruiting and supporting proliferation of tissue progenitor cells, and inducing 
vascularization (188). The innate immune system is alerted to damaged tissue by the 
secretion of alarmins (189, 190). Damage associated molecular patterns (DAMPs) attract 
innate cells (mention neutrophils and monocytes) to the site of injury (190). Antigen 
presenting cells (APCs) including macrophages and dendritic cells then interact with and 
process antigen for presentation to T cells, which are part of the adaptive immune system.  
These T cells then polarize into a specific subset based on the threat encountered 
and what cytokines are in the tissue environment. For example, IL-12 helps Th1 
polarization while IL-4 promotes Th2 polarization (191). While IL-4 secreted by TH2 T 
cells is pro-regenerative, Th1 T cells are pro-inflammatory. In OA, TH1 cells are 
sometimes found after disease onset in the synovium (192). These T cells often contain 
oligoclonal T cell populations with reactivity to chondrocytes and fibroblasts (193). 
Despite this knowledge, there is no research on the role of T cells in OA progression. A 
more recently discovered T helper subset, TH17 T cells, may also be relevant to OA 
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progression. TH17 cells produce proinflammatory cytokines including IL-17 and are 
potential initiators for pathogenesis of fibrosis. Therapies that target IL-17 result in 
remarkable improvements in psoriatic arthritis, as well as in other forms of 
spondyloarthritis (SpA) (194-196).  
There is also little known about other relevant lymphocytes such as γδ T cells, 
despite their role in other forms of arthritis such as psoriatic arthritis. γδ T cells are 
different from traditional αβ T cells because they are activated in an MHC-independent 
manner and can recognize lipid antigens, contributing to their fast effector response upon 
stimulation. γδ T cells are also an early producer of IL-17 in mouse models of 
inflammatory arthritis (197). IL-17 secreting γδ T cells are known to play a role in 
inflammatory arthritis, but their role in osteoarthritis is unknown (197). Another 
unexplored cell type in OA includes innate lymphoid cells (ILCs), a heterogeneous 
population of innate cells. Although ILCs are important in host defense, their 
dysregulation can lead to fibrosis (198). Activated group 3 innate lymphoid cells are 
enriched in psoriatic arthritis synovial fluid, suggesting that this is a cell type implicated 
in arthritis progression (199).  
Reviewing the literature, beyond the fact that T cells and macrophages are present 
in the synovium of patients with OA, there is a lack of knowledge of the immune state of 
the joint during OA disease progression (94, 192, 193). The articular cartilage is 
considered a tissue with no intrinsic regenerative capacity, which could be in part due to 
the control of the local immune response (200). Therefore, modulating the immune 
system within the joint may be a viable approach to improve its defective repair capacity. 
As senescent cells are known to sit in the joint and secrete pro-inflammatory cytokines, 
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eliminating senescent cells could potentially improve joint function by restoring healthy 
local immune cell function. Understanding the immune modulating properties of SnCs 
will also allow for new potential therapeutic applications for senolytics (201).  
Methods 
Surgical Procedures: All procedures were approved by the Johns Hopkins University 
Animal Care and Use Committee (ACUC). OA was induced by anterior cruciate ligament 
transection (ACLT) (121) in 10-week old or 72-week old male C57BL/6 mice from 
Charles River.  Two weeks after ACLT, a single 10-µL injection of either a phosphate-
buffered saline (1X PBS, from Life Technologies) vehicle control or UBX0101 was 
administered to the joint space of the operated knee via a 30-gauge needle. The joint 
cavity was opened in the sham group but the ACL was not transected.  
Histological evaluation: After 4 weeks, animals were sacrificed, and mouse knees were 
fixed in 4% paraformaldehyde (PFA), decalcified for approximately 2 weeks in 10% 
EDTA, then dehydrated and embedded in paraffin (n=3-5).  Seven-µm–thick sections 
were taken throughout the joint and stained for proteoglycans with Safranin-O and Fast 
Green (Applied biosciences) per manufacturer’s instructions. Osteoarthritis Research 
Society International (OARSI) scores are based on blinded histological assessment the 
medial plateau of the tibia (122). 
Immunohistochemistry: Slides were de-paraffinized and treated with hyaluronidase 
(0.25% in Tris buffer) before staining for IL-23 or IL-17 using Anti IL-17 antibody 
(ab79056) from Abcam at 1:400 dilution or Anti IL-23 antibody (ab45420) from Abcam 
at 1:800 dilution (each in 1% BSA/2%NGS/0.05% Tween 20) followed by secondary 
staining with a biotinylated antibody and streptavidin-peroxidase conjugated enzyme 
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using the Histostain-SP IHC kit, AEC, from ThermoFisher (cat. no. 959943), according 
to the manufacturer’s instructions. 
Immunofluorescence: Slides were de-paraffinized and antigen retrieval was performed in 
near boiling citrate ARB for 20 minutes on the bench. Slides were blocked in 1.5% BSA, 
1.5% normal goat serum, and 0.05% tween 20 for 45 minutes prior to applying primary 
antibodies. IL-17 staining was performed using rabbit anti IL-17 antibody (ab79056) 
from Abcam at 1:400 dilution. Rat anti CD4 (eBioscience, clone 4SM95) was used at a 
1:200 dilution. Secondary antibodies were applied (anti-rat AF488, anti-rabbit AF594) 
and followed by DAPI for 5 minutes before mounting.  
Gene expression analysis: Whole mouse joints were frozen in liquid nitrogen and 
homogenized using a sterile mortar and pestle (n=3-4). Inguinal lymph nodes were 
crushed in a 1.5mL Biomasher tube from Kimble. RNA was extracted using TRIzol 
reagent (Life Technologies) following the manufacturer's protocol. cDNA was 
synthesized using Superscript III reverse transcriptase (Life Technologies) following the 
manufacturer's protocol. Real-time RT-PCR was carried out using SYBR Green primers 
and a StepOnePlus Real-time PCR System (Life Technologies). Relative gene expression 
was calculated by the ΔΔCt method. The ΔCt was calculated using the reference genes 
β2-microglobulin (B2m) and β-actin (Bact).  ΔΔCt was calculated relative to the 
unoperated control group. The mouse specific primers used were the following: Bact 
forward, CCA CCG TGA AAA GAT GAC CC, Bact reverse, GTA GAT GGG CAC 
AGT GTG GG, B2m forward, CTC GGT GAC CCT GGT CTT TC, B2m reverse, GGA 
TTT CAA TGT GAG GCG GG, Acan forward, CGT TGC AGA CCA GGA GCA AT, 
Acan reverse, CGG TCA TGA AAG TGG CGG TA, Col2a1 forward, CCT CCG TCT 
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ACT GTC CAC TGA, Col2a1 reverse, ATT GGA GCC CTG GAT GAG CA, Mmp13 
forward, GTC TTC ATC GCC TGG ACC ATA, Mmp13 reverse, GGA GCC CTG ATG 
TTT CCC AT, Runx2 forward, GCC GGG AAT GAT GAG AAC TA, Runx2 reverse, 
GGT GAA ACT CTT GCC TCG TC, Il4 forward, ACA GGA GAA GGG ACG CCA T, 
Il4 reverse, ACC TTG GAA GCC CTA CAG A, Il10 forward, TCT CAC CCA GGG 
AAT TCA AA, Il10 reverse, AAG TGA TGC CCC AGG CA , Il6 forward, CCA GGT 
AGC TAT GGT ACT CCA GAA, Il6 reverse, GCT ACC AAA CTG GAT ATA ATC 
AGG A, IL1b forward, GTA TGG GCT GGA CTG TTT C, IL1b reverse, GCT GTC 
TGC TCA TTC ACG. Il17 expression in lymph nodes was assessed using the following 
SybrGreen primer: Il17a forward, TCAGCGTGTCCAAACACTGAG, Il17a 
reverse, CGCCAAGGGAGTTAAAGACTT.  
 
TaqMan primers were used for detection of IL-17A, IL-17F, and IL-23a in joint tissues. 
The IDs are: IL-23a: Mm00518984_m1, IL-17a: Mm00439618_m1, IL-17f: 
Mm00521423_m1, B2M: Mm00437762_m1, Bact: Mm04394036_g1 
PreAmp: Preamplification was performed on cDNA prior to gene expression analysis 
using TaqMan preamp master mix (Thermo Fisher). IL-17a was preamped 14 cycles and 
IL-17f, IL-23a, GM-CSF, and PTGS2 were preamped 10 cycles.  
Flow Cytometry: Whole joints and inguinal lymph nodes were harvested at 1 (7 days), 2 
(14 days) and 4 (28 days) weeks post-surgery (n=3). Harvested joint tissue was then 
finely diced and digested for 45 minutes at 37oC in 1.67 Wünsch U/ml Liberase TL 
(Roche Diagnostics) + 0.2 mg/ml DNase I (Roche Diagnostics, Risch-Rotkreuz, 
Switzerland) in serum-free RPMI-1640 medium (Gibco) on a shaker at 400 rpm. Digest 
was filtered through a 70 μm cell strainer (Fisher) then washed twice with 1XPBS. Cells 
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were stained with the following Myeloid panel: Fixable Viability Dye eFluor®780 
(eBioscience), CD45 BV605 (Biolegend, San Diego, CA), CD11b AF700 (Biolegend), 
CD11c APC (Biolegend), Ly6C PerCP-Cy5.5 (Biolegend), Ly6G Pacific Blue 
(Biolegend), F4/80 PE-Cy7 (BioLegend), MHCII AF488 (Biolegend), CD86 AmCyan 
(BioLegend), CD206 PE (BioLegend). After staining cells were fixed and analyzed on a 
BD LSRII Analyzer (BD Biosciences). LIVE/DEAD® Fixable Aqua Dead Cell Stain 
negative (live) cells were evaluated based upon percent population of T cells (CD3+), B 
cells (CD19+), dendritic cells (CD11c+), and macrophages (F4/80+). All analyses were 
performed in FlowJo Flow Cytometry Analysis Software (Treestar).  
The T cell panel displayed in Figure 1 included: Fixable Viability Dye eFluor®780 
(eBioscience), CD45 V500 (BD biosciences), CD3 AlexaFluor488 (BioLegend), CD4 
PE-Cy7 (BioLegend), CD8 BV711 (BioLegend), NK1.1 BV605 (BioLegend), Thy1.2 
Pacific Blue (BioLegend), γδ TCR PE-CF594 (BD Bioscience), IL4α PerCP-Cy5.5 
(BioLegend), IFNγ APC (Biolegend), IL-17α AF700 (Biolegend), and IL-17f PE 
(eBioscience). IL-4α, IL-17α, IL-17f, and IFNγ staining followed fixation and 
permeabilization with BD CytoFix/CytoPerm Kit (BD Biosciences).  
Fluorescence activated cell sorting: Innate lymphoid cells were sorted from joints two 
weeks post ACLT (n=3). Tissue processing is the same as described above for flow 
cytometry. Only surface staining was performed to keep the cells alive. Fixable Viability 
Dye eFluor®780 (eBioscience), CD45 V500 (BD biosciences), CD3 AlexaFluor488 
(BioLegend), CD4 PE-Cy7 (BioLegend), CD8 BV711 (BioLegend), and Thy1.2 Pacific 
Blue (BioLegend). Cells were sorted on a BDFACSAria Fusion SORP for live, CD45+, 
CD3-, CD4-, CD8- and Thy1.2+ cells defined as innate lymphoid cells. Hind Limb 
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Weight Bearing Assessment: Weight-bearing in mice was measured in the un-operated 
control animals and compared to ACLT animals receiving PBS control or UBM therapy 
using an incapacitance tester (Columbus Instruments). The percentage weight distributed 
on the ACLT limb was used as an index of joint discomfort in OA (121). The mice were 
positioned to stand on their hind paws in an angled box placed above the incapacitance 
tester so that each hind paw rested on a separate force plate. The force (g) exerted by each 
limb was measured. Three consecutive 3-second readings were taken and averaged to 
obtain the mean score (123). 
Hind Limb Responsiveness: Mice were placed on the hotplate at 55ºC. The latency 
period for hind limb response (jumping or paw-lick) was recorded as response time 
before surgery and at 2 and 4 weeks after surgery in all animal groups (121). Three 
readings were taken per mouse and averaged to obtain the mean response time for each 
time point. 
Cell culture and co-culture conditions. NIH 3T3 fibroblasts were cultured for 7 days in 
fibroblast culture medium. The cells were then irradiated with CIXD Biological 
Irradiator10Gy and collected after 7 days. The media the senescent cells (Sncs) were 
cultured in was collected at the time of cell harvesting and used in the co-culture 
experiment as “conditioned media” The day the Sncs were harvested, CD4 naive T cells 
were isolated from lymph nodes of six-week-old C57/BL6 mice. The CD4 naïve 
separation kit and MACS column from Miltenyi were used, following the manufacturer’s 
instructions. T cell purity was assessed by flow cytometry using the following panel: 
Fixable Viability Dye Aqua (Thermofisher), CD45 V500 (BD biosciences), CD3 
AlexaFluor488 (BioLegend), CD4 PE-Cy7 (BioLegend), CD8 BV711 (BioLegend), 
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CD44 BV605 (BioLegend), and CD62L APC-CY7 (BioLegend). 92.9% of the CD4 T 
cell population was naïve. Tcells and Sncs were seeded in 12 well transwell plates at 
500,000 and 300,000 cells/per well, respectively. The media used was IMDM 
supplemented with 10% FBS, 5% Penn strep and 1% sodium pyruvate. The “Snc” group 
consisted of T cells+ Sncs; “Snc+IL-2” had the addition of 500 unit/mL IL-2 into the 
culture medium’ “Snc+IL-2+TGF-β” also had the addition of 2ng/mL TGF-β; “CM” 
consisted of conditioned medium from the Sncs+IL-2+ TGF-β. Control groups consisted 
of naïve T cells+IL-2 and T cells skewed to Th17 using Th17 Cell Differentiation kit 
from R&D System. After 3 days in culture, 50% of the media was aliquoted off and fresh 
media added. After 5 total days in co-culture, T cells were harvested for flow cytometry 
and PCR analysis (n=3). T cells were stained for Fixable Viability Dye eFluor®780 
(eBioscience), CD45 V500 (BD biosciences), CD3 AlexaFluor488 (BioLegend), CD4 
PE-Cy7 (BioLegend), CD8 BV711 (BioLegend), IL4α PerCP-Cy5.5 (BioLegend), IFNγ 
APC (Biolegend), IL-17α AF700 (Biolegend), and IL-17f PE (eBiosceince). IL-4α, IL-
17α, IL-17f, and IFNγ staining followed fixation and permeabilization with BD 
CytoFix/CytoPerm Kit (BD Biosciences).  
Statistical Analysis: Statistical analysis was performed using a one-way ANOVA with 
Holm-Sidak multiple comparison correction in GraphPad Prism Software. For in vivo 
work, all groups were compared to each other. For in vitro work, each treatment was 
compared to the control group. P < 0.05 was considered significant. 
 
Results 
Immune cells and IL-17 are altered post ACLT 
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As there is no in-depth phenotyping of the immune cells present in the joint during OA 
progression, we profiled the myeloid and lymphoid cells in the joint. Of the myeloid cell 
populations, most F4/80+MHCII+ macrophages were M2-like, expressing CD206 but no 
CD86 (S. Fig. 1). There were very few CD206+ CD86+ macrophages and almost no 
CD206- CD86+ macrophages. The M2-like macrophages were increased in the joint 1 and 
2 weeks post ACLT (2.3 and 1.5-fold, respectively), and the CD206+ CD86+ M2-like 
macrophages were increased 1-week post ACLT (4.5 fold).  
Among the lymphoid cells populations analyzed, most changes were observed 1 week 
after ACLT. CD8 T cells were increased from approximately 34% of the total CD3 T cell 
fraction to approximately 43% in sham joints and 50% in ACLT joints. Additionally, γδ 
T cells were increased to 5.3% of CD3+ cells in ACLT joints over the CL joints (4.3%) 
and sham joints were increased to 5.9% over sham CL joints (4.6%). Of these γδ T cells, 
the IL-17f+ fraction was increased from 7.6% in healthy joints to 37.2% in ACLT and 
20.6% in sham joints. Additionally, IL-17+ CD4 T cells were increased from 3.2% in 
healthy joints to 9.4% in ACLT and 6.4% in sham joints. Immunofluorescence identified 
IL-17+ cells in the ACLT joint at 1-week post-surgery, whereas healthy joints had little to 
no IL-17+ cells (Fig. 1).  
ACLT increased IL-17a gene expression in joints 1, 2, and 4wks post ACLT (4,704, 
3,484, and 2,431-fold, respectively) and sham surgery increased IL-17a slowly, peaking 
at 2 weeks post-surgery and then declining by 4 weeks (3.6 fold at 1 week, 1,502-fold at 
2 weeks, and 13.9-fold fold at 4 weeks). IL-17f and IL-23 are moderately upregulated at 
1, 2, and 4wks post sham surgery (IL-17f, 2.4, 2.5, 1.8-fold respectively; IL-23, 3.7, 4.2, 
and 2.7-fold respectively). IL-10 is initially upregulated post sham surgery but diminishes 
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over time (7.5-fold at 1 week, 5.3-fold at 2 weeks, 2.1-fold at 4 weeks). GM-CSF is 
initially increased in sham surgery group (5-fold at 1 week) but increases over time in the 
ACLT group (3.6-fold at 4 weeks). PTGS2, a pro-inflammatory and pain inducing gene, 
is upregulated in both ACLT groups at 1, 2, and 4wks post-surgery (50, 42, and 3.8-fold) 
and sham groups (222, 16, 3.7-fold).  
As ILCs were altered in the joint post ACLT when assessed by flow cytometry, we sorted 
the ILCs out of the joint and then assessed for gene expression (Fig. 1c). ILCs appear to 
have an altered immune profile 2-weeks post ACLT. Nanostring analysis showed 
changes in cytokine, chemokine, T cell activation, and peptidase activities in the ACLT 
group. Taqman gene expression on specific factors indicates that RANTES (Ccl5), a T 
cell chemoattractant, is increased in the ACLT group. Additionally, the IL-17 related 
cytokines IL-17f and IL-23a are increased in the ACLT group (3.4 and 2-fold, 
respectively). Other pro-inflammatory cytokines such as IFNγ and IL-1β are increased as 
well (1.4 and 1.6-fold, respectively). ILCs are likely involved early on in OA 
inflammation and recruitment of other immune cells. 
As many immune related genes and cytokines were altered in the ACLT joint, the local 
lymphoid tissue was analyzed for possible changes. Indeed, the gene expression changes 
observed in the joint are followed by changes in the inguinal lymph nodes. ACLT 
increased IL-17a gene expression in inguinal lymph nodes 2 and 4wks post ACLT (8.65, 
2.75-fold, respectively). IL-17f is initially decreased at 1wk post-surgery in both sham 
(0.1 fold) and ACLT groups (0.4 fold) but increases over time in the ACLT group (2.2 
fold at 4wks post ACLT). IL-23a is also initially downregulated in sham (0.17 fold) and 
ACLT (0.47 fold) but returns to healthy levels at 2wks (S. Fig. 2). Additionally, IL-17a+ 
101 
 
T cells are increased in the inguinal lymph nodes 4 weeks post ACLT (S. Fig. 3a) and IL-
17a+ ILCS are also increased in the ACLT joint 4 weeks post ACLT (S. Fig. 3b). 
Clearance of SnCs reduces Th17 related cytokines  
SnCs accumulate in joints with trauma and ageing (157). In aged mice, more severe OA-
related symptoms develop after ACLT including more severe cartilage erosion and worse 
pain than in young animals (Fig. 2b, c). SnCs were shown to accumulate with ageing and 
associate with OA disease development (157). To test how young and aged animals 
respond differently to trauma, we performed ACLT surgeries on both young (10 week) 
and aged (72 week) animals. In addition to local intra-articular (IA) injection of senolytic 
treatments, we added systemic intra-peritoneal (IP) treatments of senolytic to 
systemically clear SnCs accumulated in aged animals (Fig. 2a). The clearance of SnCs in 
the joints was confirmed with reduction of the senescent cell marker Cdkn2a gene 
expression (Fig. 2b). Aged animals with combined IA and IP senolytic treatment showed 
significant decrease in cartilage erosion and pain (Fig. 2b, c). No significant improvement 
was observed with local only treatment (Fig. 2b, c, d). The OA-related disease outcomes 
of pain and cartilage erosion were reduced with systemic and local senolytic treatment 
(Fig. 2c, d). Loss of proteoglycan and cartilage thinning were attenuated in ACLT mice 
treated with combined senolytics (Fig. 2d). 
Whether attenuation of OA-related symptoms by senolysis could be related to local 
immune cell changes was studied. To study the local joint immune response, gene 
expression analysis on the signature cytokines of T helper cells was performed. IL17f, 
one of the signature cytokines secreted by Th17, is increased with ACLT, but combined 
IA and IP senolytic treatment in aged mice decreases IL-17f gene expression compared to 
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vehicle treated joints (Fig. 2e). IA and IP treatment individually reduced the average IL-
17f gene expression; however, this was not significant (Fig. 2e).  
To confirm that the reduced gene expression of IL-17f in aged mice treated with senolytic 
is solely induced by the clearance of SnCs, the p16-3MR transgenic mouse strain was 
utilized, which enables selective killing of p16 positive SnCs by ganciclovir (GCV) 
through the HSV-TK cassette. In the vehicle group, the mRNA expression of IL17f is 
increased by 30-fold, and treatment with GCV reduces IL17f  back to healthy levels (Fig. 
2f).  
Local and systemic immune response correlate with the local joints immune changes 
To investigate the impact of ACLT on local lymphoid tissue, IL17 expression was 
evaluated in the inguinal lymph nodes. The number of IL17a+cells was elevated after 
induction of OA in mouse joints (1.5 fold over the sham group) and all senolytic 
treatments reduced the average number of IL-17a+ cells, however these changes were not 
significant (IA+IP similar to sham group, IA half of sham group, IP similar to sham 
group). The relative gene expression of IL17a in the inguinal lymph node treatment 
groups correlated with the number of IL-17a+ cells. The percentage of IL4+ CD4T cells 
(displayed as a percentage of CD45+ cells) is decreased in the vehicle group relative to 
sham group by two-fold and increased with combined local and systemic senolytic 
treatment (Fig. 3d). The gene expression of IL4 was increased with systemic and 
combined treatments by 15-fold compared to vehicle group (Fig. 3e). To evaluate the 
systemic changes occurring with induction of OA, T cell populations were evaluated in 
the blood. The frequency of IL17a+ CD4 T cells in the blood was elevated with OA by 
1.5-fold and reduced with senolytic treatments (not significant) (Fig. 3f). Treatment with 
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systemic senolytic also increased the CD4/CD8 T cell ratio in the blood to from ~0.6 in 
the vehicle group to ~1 (Fig. 3g), which falls in the normal 1-2 range of healthy young 
blood CD4/CD8 ratio.  
IL17 expression correlates with senescent cells development 
Gene expression analysis was performed on aged joints and inguinal lymph nodes to 
track senescence associated marker expression of Cdkn2a and Cdkn1a (Fig. 4a-b). The 
mRNA level of T cell associated cytokines IL-17a, IL-4, and IFNy are evaluated in 
inguinal lymph nodes. IL-17a expression in the inguinal lymph node was found to have a 
similar trend in expression to Cdkn2a and Cdkn1a in the joint (Fig.4 a-b). IL-4 had the 
opposite gene expression profile, while IFNy increased in ACLT mice gradually over 
time. Given the apparent correlation between IL-17a and senescent markers, we decided 
to evaluate if removal of IL17 signaling would attenuate OA development. IL17RAKO 
mice were used to evaluate this hypothesis.  After ACLT, IL17RAKO mice exhibited less 
pain after four weeks compared to C57BL6 mice and had similar pain levels to the no 
surgery group (Fig. 4c). Four weeks post-surgery, IL17RAKO mice had less SnC burden 
compared to wild type, as indicated by 4-fold decrease of Cdkn2a expression in the joints 
(Fig. 4d).  
Senescent cells induce Th17 polarization 
Senescent cells are known to secrete the pro-inflammatory cytokines IL-6 and IL-1β, 
which are cytokines needed for Th17 polarization. To test the theory that senescent cells 
could polarize T cells to Th17, we co-cultured naïve T cells (5A) with senescent 
fibroblasts. After five days of culture, the senescent cells induced Th1 and Th17 
polarization. However, addition of TGF-β blocked Th1 polarization and enhanced Th17 
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polarization (Fig. 5B and C). The conditioned media with TGF-β did not enhance Th17 
polarization, indicating that senescent cells and TGF-β are needed for strong Th17 
phenotype (Fig. 5B). TGF-β is already present in healthy joint synovial fluid, and is 
increased in OA, suggesting that senescent cells in the joint are more likely to influence T 
cells to polarize to Th17 over Th1 (202). Th2 T cells also appeared to be downregulated 
by SnC compared to both naïve and the Th17 control group, however this trend was not 
significant (Fig. 5C). 
Discussion 
The role of senescent cells in OA progression has only recently been discovered (157). 
The role of the immune system, particularly the adaptive immune system, in OA is a 
relatively uncharted territory. Additionally, no studies to date have shown a relationship 
between the disease contributing SnCs and T cell polarization, despite the pro-
inflammatory cytokines SnCs emit. Determining the relationship between senescence and 
immune polarization will help inform future OA therapeutic treatment, especially in 
aging vs trauma induced OA populations, wherein the SnC populations and immune cell 
balance appear to be physiologically different.  
Given the relatively small amount of research on immune cells in OA, we first performed 
extensive myeloid and lymphoid profiling to identify immune changes in our anterior 
cruciate ligament transection (ACLT) model of post traumatic OA. This revealed changes 
in M2-like macrophages, ILCs, γδ T cells, CD8 T cells, and alterations in the major Th17 
cytokines IL-17f and IL-17a. Th17 cells were also altered in the draining inguinal LNs. 
There were multiple sources of IL-17 identified (T cells, γδ T cells, ILCs). IL-17 
production can be elicited without prior antigen exposure, suggesting that the 
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development of Th17 cells can occur in non-autoimmune settings like OA. Additionally, 
whereas naïve αβ T cells take 5-7 days to develop effector function after antigen priming, 
γδ T cells can make IL-17 within 12 hours after stimulation (203, 204). This suggests that 
IL-17 secreting γδ T cells could function as a link between innate and adaptive immunity 
due to their fast cytokine generation time and ability to attract other immune cells. This 
data provides additional therapeutic targets to the field of OA research.  
After identifying IL-17 as a promising therapeutic target, the possible ability of senolytics 
to modulate IL-17 levels in the joint and draining inguinal LNs, as well as the systemic 
CD4/CD8 T cell status in the blood, were studied. To test the ability of senolytic to 
modulate IL-17, a combination of both or either systemic intra-peritoneal and local intra-
articular injection of senolytic were administered to young and aged mice. We 
hypothesized that aged mice might be less responsive to local senolytic treatment due to 
overall poorer regeneration of aged mice, requiring systemic senolytic treatment to help 
restore regenerative function (169-171). Aged mice were an important component of this 
study not only because the estimated incidence of symptomatic knee OA diagnosis is 
highest among adults age 55-64 (168), but because aged related SnC are likely different 
from trauma induced SnC.  
The ability of combined local and systemic senolytic to reduce IL-17 gene expression and 
increase IL-4 immunofluorescence signal in aged mice over that of local or systemic 
treatment alone is very intriguing. The fact that the local lymphoid tissue also has similar 
trends suggests that the systemic senolytic treatment is supporting the local joint 
regeneration and immune cell changes. One possible reason the systemic senolytic 
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treatment has an impact on tissue regeneration may be related to its ability to shift the 
systemic CD4/CD8 T cell ratio in favor of CD4 T cells. In aged human OA peripheral 
blood, CD4 T cells are lower than in aged matched controls, and in synovial tissue, there 
is a shift towards increased CD8 T cells (205). The aged and OA associated skewing of 
the T cell repertoire to CD8 could possibly result in or reflects a decreased healthy 
immune response, as CD8 T cells are primarily cytotoxic compared to CD4 T cells, 
which help generate specific immune responses. 
The above observation of modulation of T cell polarization with senolytic treatment in 
vivo was also observed in vitro, supporting the idea that SnC influence T cell 
polarization. Additionally, it is known that inhibition of TGF-β signaling in mesenchymal 
stem cells of subchondral bone attenuates osteoarthritis. This could reflect a change in T 
cell polarization from Th17 to Th1 due to loss of the TGF-β signal (as is implied by our 
in vitro results).  
Conclusion 
Our study results demonstrate that Th17 signatures are altered in the mouse post-
traumatic model of OA and that senolytic treatment can reduce Th17. A direct connection 
between senescent cells and Th17 polarization was demonstrated in this study. Future 
studies should examine IL-17 neutralization to determine if direct inhibition of this 








Chapter 4 Figures 
Figure 1. IL-17 is altered post ACLT 
 
A. Flow cytometry revealed early lymphoid changes in the joint 1-week post ACLT. B. 
Whole joint gene expression. IL-17a gene expression is increased in joints 1, 2, and 4wks 
post ACLT, and increases in sham joints up until 2 weeks post-surgery and then 
diminishes. IL-17f and IL-23 are moderately upregulated at 1, 2, and 4wks post sham 
surgery. IL-10 is initially upregulated post sham surgery but diminishes over time. C. 
Nanostring revealed altered gene expression of sorted ILCs from ACLT joints 2wks post 
ACLT, particularly in IL-17 related cytokines. D. Inguinal lymph node gene expression. 
IL-17a is increased two and four weeks post ACLT. IL-17f increases over time. Right: 
immunofluorescence of inguinal lymph node two weeks post ACLT. Th17 cells are 
observed in the subcapsular sinus. E. Immunofluorescence of a healthy joint (left) and 
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one-week post ACLT joint (right). ACLT joints exhibit IL-17 staining in the synovium 
and cartilage. F. Immunohistochemistry of human OA synovium and cartilage. Both 

























Figure 2. Clearance of SnCs attenuates the development of OA and reduces the Th17 related 
expressions in joints.  
 
 (a) Schematic of the time course for the experiment in b-f. Male C57BL6 mice 
undergoing ACLT were systemically or locally treated with vehicle (Veh), Nutlin, or 
ABT263. (b) Quantification of gene expression for Cdkn2a in articular joints on day 28 
after surgery. (c) The percentage of weight placed on the operated limb versus the 
contralateral control. (d) Representative images of Safranin O and fast green staining. (e) 
Quantification of gene expression for IL17f in articular joints on day 28 after surgery. (f) 
Quantification of gene expression for IL17f in p16-3MR mice (10 week) articular joints 
treated on day 28 after surgery.  
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Figure 3. Local and systemic immune response correlate with the local joints immune changes in 
aged and young mice
 
Panels a-g are data from aged mice, panel h is from young mice. (a) Frequency of IL17a+ 
cells in inguinal lymph nodes. Representative data of each group is shown. (b) Cell 
Number of IL17a+ cells in inguinal lymph nodes. (c) Quantification of IL17a gene 
expression in inguinal lymph nodes. (d) Frequency of IL4+ cells in inguinal lymph nodes. 
(e) Quantification of IL4 gene expression in inguinal lymph nodes. (f) Frequency of 
IL17a+ cells in peripheral blood. (g) CD4/CD8 ratio in peripheral blood. (h)  




Figure 4. IL17 expression parallels senescent cells development, and IL17RAKO mice attenuates 
the development of pain
 
(a) Quantification of Cdkn2a and Cdkn1a gene expressions in joints of young animals (no 
surgery) and aged animals (no surgery, 2 week and 4-week post-surgery). (b) 
Quantification of IL17a, IL4, and IFNy gene expressions in inguinal lymph nodes of 
young animals (no surgery) and aged animals (no surgery, 2 week and 4-week post-
surgery). (c) The percentage of weight placed on the operated limb versus the 
contralateral control. (d) Quantification of Cdkn2a in articular joints of IL17RAKO, 





Figure 5. Senescent cells induce Th17 polarization 
 
T cell subsets as analyzed by flow cytometry. A. Outline of experiment. Flow plot 
demonstrates the increased purity of naïve CD4 T cells after isolation. B-C flow 
cytometry characterizing T cell populations 5 days after co-culture with SnC. Naïve= T 
cells+IL-2. Other conditions note what was added to the naïve T cells. CM=SnC 
conditioned media+IL-2+TGF-β. B. Representative flow plot showing IL-17a and IL-17f 
intracellular cytokine staining. C. Representative flow plot showing IFNγ and IL-4 









S. Figure 1. ACLT induces macrophage infiltration 
 
To characterize myeloid cells in whole knee joint post ACLT and sham surgery, joints 
were processed for flow cytometry analysis and stained with myeloid markers A. 
Immunophenotyping of macrophages. B. Quantification of the number of F4/80+ 
macrophages in the post-surgery. C. Further immunophenotyping was carried out on the 
M2 marker CD206 and M1 marker CD86. D. Quantification of the number of CD206+ 
CD86LO macrophages in the knee joint. E. Quantification of the number of CD206+ 






















S. Fig. 3. ACLT alters the local lymphoid tissues 
 
 
Flow cytometry analysis on the inguinal lymph nodes post-surgery. A. IL-17a+ T cells are 
increased in the inguinal lymph nodes 4 weeks post ACLT. B. IL-17a+ ILCS are also 













Gene expression analysis on inguinal lymph nodes harvested 3 days post therapeutic injection. 














































In the enclosed research, biomaterials such as ECM and hyaluronic acid binding peptide-
polymer were implemented to reduce OA progression in a mouse model of post traumatic 
OA. Our results indicate that urinary bladder matrix (UBM) is a promising biomaterial 
for OA that should be tested in a larger animal model before clinical testing. As this 
material is already clinically approved for muscle wound regeneration and healing 
chronic wounds, it could easily be translated in OA treatment. Additionally, another 
ECM, AmnioFix® Injectable, a Human Amnion/Chorion Membrane ECM, has been 
given a designation for use in the treatment of Osteoarthritis (OA) of the knee. This ECM 
could serve as an example for other ECMs such as UBM to be given designations for 
OA.  
Our results also indicate that hyaluronic acid binding peptide-polymer merits testing in a 
larger animal model for disease modifying activity alone and with hyaluronic acid 
supplementation. Hyaluronic acid binding peptide-polymer can potentially replace cross-
linked HA injections, which sometimes cause severe inflammatory reactions. 
Additionally, the use of hyaluronic acid binding peptide-polymer as a delivery vehicle for 
other OA disease modifying drugs should be pursued, particularly for drugs that need to 
localize to the cartilage surface to be efficacious.  
During these biomaterials driven studies, aged mice were found to be an improved 
predictor of therapeutic efficacy over young mice based on therapeutic outcomes tracking 
more closely with patient outcomes- in the case of Orthovisc®. This work implementing 
biomaterials led to the deeper dissection of the immune system in OA progression in the 
hope to identify new adaptive and innate immune cells involved in the disease. This 
revealed changes in M2-like macrophages, ILCs, γδ T cells, CD8 T cells, and alterations 
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in the major Th17 cytokines IL-17f and IL-17a. Th17 cells were also altered in the 
draining inguinal LNs. There were multiple sources of IL-17 identified (T cells, γδ T 
cells, ILCs). 
Although we identified IL-17 as a potential player in OA progression, the effect of 
neutralizing IL-17a and f on OA progression still needs to be performed to assess whether 
alteration of this cytokine directly impacts disease progression. Additionally, increasing 
IL-17, either by systemic IP or local IA injection, should be performed in conjunction 
with ACLT to determine whether IL-17 alone worsens OA disease progression. These 
experiments will help definitively determine the role of IL-17 in OA progression, which 
is heavily suggested by the experiments performed as described in chapter 4.  
The work in chapter 4 describes global joint immune cell changes including from the 
subchondral bone, synovium, cartilage and ligaments. All these tissues are involved in 
OA progression and are known to provide pro-inflammatory signals that aid in OA 
progression. We located many IL-17+ cells among the synovium, inguinal LNs, and 
sometimes chondrocytes, however the contribution of each of these tissues to OA 
progression in the context of immune signaling needs to be further dissected. Currently 
the synovium is thought to control and contribute most of the immune cells and cytokines 
found in the joint. However, the bone marrow should be considered as a major player as 
it is the site of B cell production and maturation. Additionally, precursors for T cells, 
monocytes, and neutrophils are made in the bone marrow (206). The bone marrow is also 
home to many of these immune cells, including acting as a reservoir for mature, antigen 
experienced CD4 and CD8 T cells (207). The subchondral bone marrow could act as a 
reservoir for these cells to migrate in and out of the vascular channels of the bone and 
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contribute to arthritis progression. Chondrocytes are also often ignored when discussing 
the immune interface in the joint. However, chondrocytes express many immune related 
receptors on their surface such as TLR2/4, which may allow them to be more responsive 
and reactive to cytokine signaling than is currently known. This also brings up the 
question of whether cartilage is immune privileged. Studies on cartilage immune 
privilege have been inconclusive. It may simply be the case that the dense cartilage ECM 
prevents immune cells from interacting with chondrocytes, leading to the appearance of 
immune privilege in some cases (208-212). However, the cell signaling that chondrocytes 
participate in suggests that chondrocytes are more diverse than is acknowledged and may 
actively participate in immune signaling. 
In summary, we have optimized and validated the disease modifying biomaterial 
hyaluronic acid binding peptide-polymer in the post traumatic mouse model of OA as 
well as defined new immune cell targets for future testing in OA therapy. Future work 
will include identification of immunomodulatory reagents that will positively modulate 
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